UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

________________________________________________

FORM 10-Q

________________________________________________


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, ~~2021~~2022


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 1-9810

Owens & Minor, Inc.

(Exact name of Registrant as specified in its charter)


Virginia			54-1701843
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)

9120 Lockwood Boulevard	Mechanicsville	Virginia	23116
(Address of principal executive offices)			(Zip Code)

Post Office Box 27626, Richmond, Virginia			23261-7626
(Mailing address of principal executive offices)			(Zip Code)

Registrant’s telephone number, including area code (804) 723-7000

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $2 par value per share

OMI

New York Stock Exchange

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “larger accelerated filer”, “accelerated filer”, “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐☒	Accelerated filer	☒☐
Non-accelerated filer	☐ (Do not check if a smaller reporting company)	Smaller reporting company	☐
Emerging growth company	☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.			☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of Owens & Minor, Inc.’s common stock outstanding as of October ~~31, 2021,~~27, 2022 was ~~75,455,760~~76,234,454 shares.

Table of Contents

Owens & Minor, Inc. and Subsidiaries

Index


Part I. Financial Information		Page

Item 1.	Financial Statements	3
	Consolidated Statements of Operations—Three and Nine Months Ended September 30, ~~2021~~2022 and ~~2020~~2021	3
	Consolidated Statements of Comprehensive ~~Income (Loss)—~~Income—Three and Nine Months Ended ~~September~~Sept ember 30, ~~2021~~2022 and ~~2020~~2021	4
	Consolidated Balance Sheets—~~September~~Sept ember 30, ~~2021~~2022 and December 31, ~~2020~~2021	5
	Consolidated Statements of Cash Flows—Nine Months Ended September 30, ~~2021~~2022 and ~~2020~~2021	6
	Consolidated Statements of Changes in Equity—Three and Nine Months Ended September 30, ~~2021~~2022 and ~~2020~~2021	7
	Notes to Consolidated Financial Statements	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2022
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2932
Item 4.	Controls and Procedures	3033
Part II. Other Information

Item 1.	Legal Proceedings	3033
Item 1A.	Risk Factors	3033
Item 2.	Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities	3233
Item 5.	Other Information	33
Item 6.	Exhibits	3234

Table of Contents

Part I. Financial Information

Item 1. Financial Statements

Owens & Minor, Inc. and Subsidiaries

Consolidated Statements of Operations

(unaudited)

Three Months Ended
September 30, Nine Months Ended
September 30,
(in thousands, except per share data) 2021 2020 2021 2020
Net revenue $ 2,502,175 $ 2,187,928 $ 7,318,169 $ 6,118,340
Cost of goods sold 2,173,336 1,843,589 6,146,511 5,236,035
Gross margin 328,839 344,339 1,171,658 882,305
Distribution, selling and administrative expenses 262,457 262,538 849,255 758,320
Acquisition-related and exit and realignment charges 6,380 6,382 20,967 18,500
Other operating income, net (2,873) (134) (5,016) (3,020)
Operating income 62,875 75,553 306,452 108,505
Interest expense, net 11,572 20,975 36,784 65,923
Loss on extinguishment of debt — 308 40,433 2,580
Other expense (income), net 799 785 2,397 (1,193)
Income from continuing operations before income taxes 50,504 53,485 226,838 41,195
Income tax provision 6,375 7,404 47,224 3,863
Income from continuing operations, net of tax 44,129 46,081 179,614 37,332
Loss from discontinued operations, net of tax — — — (58,203)
Net income (loss) $ 44,129 $ 46,081 $ 179,614 $ (20,871)
Basic income (loss) per common share:
Income from continuing operations $ 0.60 $ 0.76 $ 2.47 $ 0.61
Loss from discontinued operations — — — (0.95)
Net income (loss) $ 0.60 $ 0.76 $ 2.47 $ (0.34)
Diluted income (loss) per common share:
Income from continuing operations $ 0.58 $ 0.76 $ 2.38 $ 0.61
Loss from discontinued operations — — — (0.95)
Net income (loss) $ 0.58 $ 0.76 $ 2.38 $ (0.34)


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands, except per share data)	2022		2021		2022		2021
Net revenue	$	2,497,401	$	2,502,175	$	7,404,368	$	7,318,169
Cost of goods sold	1,984,122		2,173,336		5,985,136		6,146,511
Gross margin	513,279		328,839		1,419,232		1,171,658
Distribution, selling and administrative expenses	445,259		262,457		1,177,812		849,255
Acquisition-related and exit and realignment charges	8,898		6,380		50,048		20,967
Other operating income, net	(1,125)		(2,873)		(5,020)		(5,016)
Operating income	60,247		62,875		196,392		306,452
Interest expense, net	39,869		11,572		87,727		36,784
Loss on extinguishment of debt	—		—		—		40,433
Other expense, net	783		799		2,347		2,397
Income before income taxes	19,595		50,504		106,318		226,838
Income tax provision	7,098		6,375		25,937		47,224
Net income	$	12,497	$	44,129	$	80,381	$	179,614

Net income per common share:
Basic	$	0.17	$	0.60	$	1.08	$	2.47
Diluted	$	0.16	$	0.58	$	1.05	$	2.38

See accompanying notes to consolidated financial statements.

Table of Contents

Owens & Minor, Inc. and Subsidiaries

Consolidated Statements of Comprehensive Income ~~(Loss)~~

(unaudited)


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	(in thousands)	2021		2020		2021		2020		(in thousands)	2022		2021		2022		2021
Net income (loss)		$	44,129	$	46,081	$	179,614	$	(20,871)
Other comprehensive income (loss), net of tax:
Net income										Net income	$	12,497	$	44,129	$	80,381	$	179,614
Other comprehensive income (loss) net of tax:										Other comprehensive income (loss) net of tax:
Currency translation adjustments	Currency translation adjustments	(12,014)		5,173		(26,724)		7,003		Currency translation adjustments	(19,986)		(12,014)		(39,604)		(26,724)
Change in unrecognized net periodic pension costs	Change in unrecognized net periodic pension costs	395		167		552		932		Change in unrecognized net periodic pension costs	288		395		774		552
Change in gains and losses on derivative instruments	Change in gains and losses on derivative instruments	—		1,681		20,044		(9,792)		Change in gains and losses on derivative instruments	9,167		—		11,931		20,044
Total other comprehensive income (loss), net of tax		(11,619)		7,021		(6,128)		(1,857)
Comprehensive income (loss)		$	32,510	$	53,102	$	173,486	$	(22,728)
Total other comprehensive (loss), net of tax										Total other comprehensive (loss), net of tax	(10,531)		(11,619)		(26,899)		(6,128)
Comprehensive income										Comprehensive income	$	1,966	$	32,510	$	53,482	$	173,486

See accompanying notes to consolidated financial statements.

Table of Contents

Owens & Minor, Inc. and Subsidiaries

Consolidated Balance Sheets

(unaudited)


		September 30,		December 31,			September 30,		December 31,
(in thousands, except per share data)	(in thousands, except per share data)	2021		2020		(in thousands, except per share data)	2022		2021
Assets	Assets					Assets
Current assets	Current assets					Current assets
Cash and cash equivalents	Cash and cash equivalents	$	39,759	$	83,058	Cash and cash equivalents	$	76,770	$	55,712
Accounts receivable, net of allowances of $19,273 and $19,087		759,744		700,792
Accounts receivable, net of allowances of $11,016 and $18,003						Accounts receivable, net of allowances of $11,016 and $18,003	751,970		681,564
Merchandise inventories	Merchandise inventories	1,514,387		1,233,751		Merchandise inventories	1,508,443		1,495,972
Other current assets	Other current assets	84,335		118,264		Other current assets	104,734		88,564
Total current assets	Total current assets	2,398,225		2,135,865		Total current assets	2,441,917		2,321,812
Property and equipment, net of accumulated depreciation of $320,389 and $284,126		308,463		315,662
Property and equipment, net of accumulated depreciation of $414,920 and $334,500						Property and equipment, net of accumulated depreciation of $414,920 and $334,500	575,799		317,235
Operating lease assets	Operating lease assets	184,554		144,755		Operating lease assets	275,833		194,006
Goodwill	Goodwill	386,693		394,086		Goodwill	1,631,336		390,185
Intangible assets, net	Intangible assets, net	209,789		243,351		Intangible assets, net	464,077		209,745
Other assets, net	Other assets, net	96,395		101,920		Other assets, net	149,620		103,568
Total assets	Total assets	$	3,584,119	$	3,335,639	Total assets	$	5,538,582	$	3,536,551
Liabilities and equity	Liabilities and equity					Liabilities and equity
Current liabilities	Current liabilities					Current liabilities
Accounts payable	Accounts payable	$	1,118,753	$	1,000,186	Accounts payable	$	1,156,230	$	1,001,959
Accrued payroll and related liabilities	Accrued payroll and related liabilities	100,171		109,447		Accrued payroll and related liabilities	106,618		115,858
Other current liabilities	Other current liabilities	206,094		236,094		Other current liabilities	339,526		226,204
Total current liabilities	Total current liabilities	1,425,018		1,345,727		Total current liabilities	1,602,374		1,344,021
Long-term debt, excluding current portion	Long-term debt, excluding current portion	959,485		986,018		Long-term debt, excluding current portion	2,547,059		947,540
Operating lease liabilities, excluding current portion	Operating lease liabilities, excluding current portion	154,009		119,932		Operating lease liabilities, excluding current portion	215,022		162,241
Deferred income taxes	Deferred income taxes	37,093		50,641		Deferred income taxes	83,473		35,310
Other liabilities	Other liabilities	121,509		121,267		Other liabilities	123,817		108,938
Total liabilities	Total liabilities	2,697,114		2,623,585		Total liabilities	4,571,745		2,598,050
Commitments and contingencies	Commitments and contingencies	0		0		Commitments and contingencies
Equity	Equity					Equity
Common stock, par value $2 per share; authorized - 200,000 shares; issued and outstanding - 75,429 shares and 73,472 shares		150,858		146,944
Common stock, par value $2 per share; authorized - 200,000 shares; issued and outstanding - 76,217 shares and 75,433 shares						Common stock, par value $2 per share; authorized - 200,000 shares; issued and outstanding - 76,217 shares and 75,433 shares	152,434		150,865
Paid-in capital	Paid-in capital	434,952		436,597		Paid-in capital	413,894		440,608
Retained earnings	Retained earnings	345,832		167,022		Retained earnings	467,999		387,619
Accumulated other comprehensive loss	Accumulated other comprehensive loss	(44,637)		(38,509)		Accumulated other comprehensive loss	(67,490)		(40,591)
Total equity	Total equity	887,005		712,054		Total equity	966,837		938,501
Total liabilities and equity	Total liabilities and equity	$	3,584,119	$	3,335,639	Total liabilities and equity	$	5,538,582	$	3,536,551

See accompanying notes to consolidated financial statements.

Table of Contents

Owens & Minor, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(unaudited)

Nine Months Ended September 30,
(in thousands) 2021 2020
Operating activities:
Net income (loss) $ 179,614 $ (20,871)
Adjustments to reconcile net income (loss) to cash provided by operating activities:
Depreciation and amortization 68,142 69,494
Share-based compensation expense 19,078 15,275
Loss on divestiture — 65,472
Loss on extinguishment of debt 40,433 2,580
Provision for losses on accounts receivable 19,270 9,583
Deferred income tax (benefit) expense (18,286) 25,017
Changes in operating lease right-of-use assets and lease liabilities 1,190 (1,328)
Changes in operating assets and liabilities:
Accounts receivable (84,381) (20,173)
Merchandise inventories (284,188) 52,605
Accounts payable 120,821 136,156
Net change in other assets and liabilities (8,341) (69,117)
Other, net 20,484 3,503
Cash provided by operating activities 73,836 268,196
Investing activities:
Proceeds from divestiture — 133,000
Additions to property and equipment (26,446) (21,678)
Additions to computer software (6,179) (4,702)
Proceeds from sale of property and equipment 41 178
Proceeds from cash surrender value of life insurance policies — 6,032
Cash (used for) provided by investing activities (32,584) 112,830
Financing activities:
Proceeds from issuance of debt 574,900 150,000
Repayments under revolving credit facility, net (90,900) (107,900)
Repayments of debt (553,140) (270,399)
Financing costs paid (13,912) (10,367)
Cash dividends paid (548) (467)
Payment for termination of interest rate swaps (15,434) —
Other, net (18,188) (5,822)
Cash used for financing activities (117,222) (244,955)
Effect of exchange rate changes on cash and cash equivalents (2,454) 6,721
Net (decrease) increase in cash, cash equivalents and restricted cash (78,424) 142,792
Cash, cash equivalents and restricted cash at beginning of period 134,506 84,687
Cash, cash equivalents and restricted cash at end of period $ 56,082 $ 227,479
Supplemental disclosure of cash flow information:
Income taxes paid (received), net of refunds $ 83,606 $ (1,892)
Interest paid $ 32,035 $ 61,271


	Nine Months Ended September 30,
(in thousands)	2022		2021
Operating activities:
Net income	$	80,381	$	179,614
Adjustments to reconcile net income to cash provided by operating activities:
Depreciation and amortization	155,438		68,142
Share-based compensation expense	15,765		19,078
Loss on extinguishment of debt	—		40,433
Provision for losses on accounts receivable	5,289		19,270
Deferred income tax expense (benefit)	2,991		(18,286)
Changes in operating lease right-of-use assets and lease liabilities	922		1,190
Gain on sale and dispositions of property and equipment	(17,002)		—
Changes in operating assets and liabilities:
Accounts receivable	7,417		(84,381)
Merchandise inventories	(6,823)		(284,188)
Accounts payable	30,424		120,821
Net change in other assets and liabilities	(45,423)		(8,341)
Other, net	8,666		20,484
Cash provided by operating activities	238,045		73,836
Investing activities:
Acquisition, net of cash acquired	(1,684,607)		—
Additions to property and equipment	(109,275)		(26,446)
Additions to computer software	(5,873)		(6,179)
Proceeds from sale of property and equipment	29,720		41
Other, net	(1,670)		—
Cash used for investing activities	(1,771,705)		(32,584)
Financing activities:
Proceeds from issuance of debt	1,691,000		574,900
Borrowings (repayments) under revolving credit facility, net and accounts receivable securitization program	30,000		(90,900)
Repayments of debt	(3,000)		(553,140)
Borrowings under amended accounts receivable securitization program	697,700		—
Repayments under amended accounts receivable securitization program	(770,700)		—
Financing costs paid	(42,602)		(13,912)
Cash dividends paid	—		(548)
Payment for termination of interest rate swaps	—		(15,434)
Other, net	(41,813)		(18,188)
Cash provided by (used for) financing activities	1,560,585		(117,222)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(5,752)		(2,454)
Net increase (decrease) in cash, cash equivalents and restricted cash	21,173		(78,424)
Cash, cash equivalents and restricted cash at beginning of period	72,035		134,506
Cash, cash equivalents and restricted cash at end of period	$	93,208	$	56,082
Supplemental disclosure of cash flow information:
Income taxes paid, net of refunds	$	33,568	$	83,606
Interest paid	$	61,889	$	32,035
Noncash investing activity:
Unpaid purchases of property and equipment and software at end of period	$	63,158	$	—

See accompanying notes to consolidated financial statements.

Table of Contents

Owens & Minor, Inc. and Subsidiaries

Consolidated Statements of Changes in Equity

(unaudited)


(in thousands, except per share data)	(in thousands, except per share data)	Common Shares Outstanding	Common Stock ($2 par value )		Paid-In Capital		Retained Earnings		Accumulated Other Comprehensive Loss		Total Equity		(in thousands, except per share data)	Common Shares Outstanding	Common Stock ($2 par value )		Paid-In Capital		Retained Earnings		Accumulated Other Comprehensive Loss		Total Equity
Balance, December 31, 2021													Balance, December 31, 2021	75,433	$	150,865	$	440,608	$	387,619	$	(40,591)	$	938,501
Net income													Net income						39,279				39,279
Other comprehensive loss													Other comprehensive loss								(598)		(598)
Share-based compensation expense, exercises and other													Share-based compensation expense, exercises and other	653	1,307		(30,867)						(29,560)
Balance, March 31, 2022													Balance, March 31, 2022	76,086	152,172		409,741		426,898		(41,189)		947,622
Net income													Net income						28,604				28,604
Other comprehensive loss													Other comprehensive loss								(15,770)		(15,770)
Share-based compensation expense, exercises and other													Share-based compensation expense, exercises and other	85	171		(1,968)						(1,797)
Balance, June 30, 2022													Balance, June 30, 2022	76,171	152,343		407,773		455,502		(56,959)		958,659
Net income													Net income						12,497				12,497
Other comprehensive loss													Other comprehensive loss								(10,531)		(10,531)
Share-based compensation expense, exercises and other													Share-based compensation expense, exercises and other	46	91		6,121						6,212
Balance, September 30, 2022													Balance, September 30, 2022	76,217	$	152,434	$	413,894	$	467,999	$	(67,490)	$	966,837

Balance, December 31, 2020	Balance, December 31, 2020	73,472	$	146,944	$	436,597	$	167,022	$	(38,509)	$	712,054	Balance, December 31, 2020	73,472	$	146,944	$	436,597	$	167,022	$	(38,509)	$	712,054
Net income	Net income						69,589				69,589		Net income						69,589				69,589
Other comprehensive income	Other comprehensive income								7,903		7,903		Other comprehensive income								7,903		7,903
Dividends declared ($0.0025 per share)	Dividends declared ($0.0025 per share)						(434)				(434)		Dividends declared ($0.0025 per share)						(434)				(434)
Share-based compensation expense, exercises and other	Share-based compensation expense, exercises and other	1,628	3,256		(6,107)						(2,851)		Share-based compensation expense, exercises and other	1,628	3,256		(6,107)						(2,851)
Balance, March 31, 2021	Balance, March 31, 2021	75,100	150,200		430,490		236,177		(30,606)		786,261		Balance, March 31, 2021	75,100	150,200		430,490		236,177		(30,606)		786,261
Net income	Net income						65,896				65,896		Net income						65,896				65,896
Other comprehensive loss	Other comprehensive loss								(2,412)		(2,412)		Other comprehensive loss								(2,412)		(2,412)
Dividends declared ($0.0025 per share)	Dividends declared ($0.0025 per share)						(187)				(187)		Dividends declared ($0.0025 per share)						(187)				(187)
Share-based compensation expense, exercises and other	Share-based compensation expense, exercises and other	295	591		(2,130)						(1,539)		Share-based compensation expense, exercises and other	295	591		(2,130)						(1,539)
Balance, June 30, 2021	Balance, June 30, 2021	75,395	150,791		428,360		301,886		(33,018)		848,019		Balance, June 30, 2021	75,395	150,791		428,360		301,886		(33,018)		848,019
Net income	Net income						44,129				44,129		Net income						44,129				44,129
Other comprehensive loss	Other comprehensive loss								(11,619)		(11,619)		Other comprehensive loss								(11,619)		(11,619)
Dividends declared ($0.0025 per share)	Dividends declared ($0.0025 per share)						(183)				(183)		Dividends declared ($0.0025 per share)						(183)				(183)
Share-based compensation expense, exercises and other	Share-based compensation expense, exercises and other	34	67		6,592						6,659		Share-based compensation expense, exercises and other	34	67		6,592						6,659
Balance, September 30, 2021	Balance, September 30, 2021	75,429	$	150,858	$	434,952	$	345,832	$	(44,637)	$	887,005	Balance, September 30, 2021	75,429	$	150,858	$	434,952	$	345,832	$	(44,637)	$	887,005

Balance, December 31, 2019		62,843	$	125,686	$	251,401	$	137,774	$	(52,707)	$	462,154
Net loss							(11,324)				(11,324)
Other comprehensive loss									(39,405)		(39,405)
Dividends declared ($0.0025 per share)							(127)				(127)
Share-based compensation expense, exercises and other		42	84		4,956						5,040
Balance, March 31, 2020		62,885	125,770		256,357		126,323		(92,112)		416,338
Net loss							(55,627)				(55,627)
Other comprehensive income									30,527		30,527
Dividends declared ($0.0025 per share)							(156)				(156)
Share-based compensation expense, exercises and other		852	1,704		2,376						4,080
Balance, June 30, 2020		63,737	127,474		258,733		70,540		(61,585)		395,162
Net income							46,081				46,081
Other comprehensive income									7,021		7,021
Dividends declared ($0.0025 per share)							(156)				(156)
Share-based compensation expense, exercises and other		(21)	(42)		3,269						3,227
Balance, September 30, 2020		63,716	$	127,432	$	262,002	$	116,465	$	(54,564)	$	451,335

See accompanying notes to consolidated financial statements.

Table of Contents

Owens & Minor, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

(unaudited)

(in thousands, except per share data, unless otherwise indicated)

Note 1—Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited consolidated financial statements include the accounts of Owens & Minor, Inc. and the subsidiaries it controls (we, us, our or ~~our)~~the Company) and contain all adjustments (which are comprised only of normal recurring accruals and use of estimates) necessary to conform with U.S. generally accepted accounting principles (GAAP). All significant intercompany accounts and transactions have been eliminated. The ~~Movianto business~~represented a component that met accounting requirements to be classified as discontinued operations for the nine months ended September 30, 2020. In accordance with GAAP, the results of operations of the Movianto business are presented as discontinued operations through June 18, 2020 (the Divestiture Date) and, as such, have been excluded from continuing operations for the nine months ended September 30, 2020. With the exception of Note 3, the Notes to Consolidated Financial Statements reflect the continuing operations of Owens & Minor, Inc. and its subsidiaries. See Note 3 for additional information regarding discontinued operations. The results of operations for interim periods are not necessarily indicative of the results expected for the full year.

Our business has two distinct segments: Products & Healthcare Services and Patient Direct. Products & Healthcare Services provides distribution, outsourced logistics and value-added services, and manufactures and sources medical surgical products through our production and kitting operations. Patient Direct expands our business along the continuum of care through delivery of disposable medical supplies sold directly to patients and home health agencies and is a leading provider of integrated home healthcare equipment and related services in the United States. Beginning with the quarter ended March 31, 2022, we have reported financial results using this two segment structure and have recastour prior year segment results on the same basis.

On March 29, 2022, we completed the acquisition of 100% of Apria, Inc. pursuant to the Agreement and Plan of Merger dated January 7, 2022, in exchange for approximately $1.7 billion, net of cash acquired. Refer to Note 3 for additional details.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires us to make assumptions and estimates that affect reported amounts and related disclosures. Actual results may differ from these estimates.

Cash, Cash Equivalents and Restricted Cash

Cash, cash equivalents and restricted cash includes cash and marketable securities with an original maturity or maturity at acquisition of three months or less. Cash, cash equivalents and restricted cash are stated at cost. Nearly all of our cash, cash equivalents and restricted cash are held in cash depository accounts in major banks in ~~the United States,~~North America, Europe, and Asia. Cash that is held by a major bank and has restrictions on its availability to us is classified as restricted cash. Restricted cash included in Other assets, net as of September 30, 2022 and December 31, 2021 primarily represents cash held in an escrow account as required by the Centers for Medicare & Medicaid Services (CMS) in conjunction with the Bundled Payments for Care Improvement (BPCI) ~~initiatives.~~initiatives related to wind-down costs of Fusion5.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the accompanying consolidated balance sheets that sum to the total of those same amounts presented in the accompanying consolidated statements of cash flows.


	September 30, 2022		December 31, 2021
Cash and cash equivalents	$	76,770	$	55,712
Restricted cash included in Other assets, net	16,438		16,323
Total cash, cash equivalents, and restricted cash	$	93,208	$	72,035

September 30, 2021 December 31, 2020
Cash and cash equivalents $ 39,759 $ 83,058
Restricted cash included in Other current assets — 35,126
Restricted cash included in Other assets, net 16,323 16,322
Total cash, cash equivalents, and restricted cash $ 56,082 $ 134,506
Property and Equipment, net

Property and equipment are stated at cost less accumulated depreciation. Depreciation and amortization expense for financial reporting purposes is computed on a straight-line method over the estimated useful lives of the assets or, for capital leases and leasehold improvements, over the term of the lease, if shorter. In general, the estimated useful lives for computing depreciation and amortization are three to 15 years for machinery and equipment, five to 40 years for buildings, one to 10 years for patient equipment, and up to 15 years for leasehold and land improvements. Straight-line and accelerated methods of depreciation are used for income tax purposes. Normal maintenance and repairs are expensed as incurred, and renovations and

Table of Contents

betterments are capitalized. We suspend depreciation and amortization on assets that are held for sale. In addition, we record capital-related government grants earned as reductions to the cost of property and equipment; and associated unpaid liabilities and grant proceeds receivable are considered non-cash changes in such balances for purposes of preparation of our consolidated statements of cash flows. Patient equipment consists of medical equipment rented to patients on a month-to-month basis. Patient equipment depreciation is classified in our consolidated statements of operations within cost of goods sold as the equipment is rented to patients as part of our primary operations within the Patient Direct segment.

Revenue Recognition

Our revenue is primarily generated from sales contracts with customers. Under most of our distribution and product sales arrangements, our performance obligations are limited to delivery of products to a customer upon receipt of a purchase order. For these arrangements, we recognize revenue at the point in time when shipment is completed, as control passes to the customer upon product receipt.

Revenue for activity-based fees and other services is recognized over time as activities are performed. Depending on the specific contractual provisions and nature of the performance obligation, revenue from services may be recognized on a straight-line basis over the term of the service, on a proportional performance model, based on level of effort, or when final deliverables have been provided.

Our contracts sometimes allow for forms of variable consideration including rebates, discounts, performance guarantees, and implicit price concessions. In these cases, we estimate the amount of consideration to which we will be entitled in exchange for transferring the product or service to the customer. Rebates and customer discounts are estimated based on contractual terms or historical experience and we maintain an accrual for rebates or discounts that have been earned but are unpaid. When we have implicit price concessions, we determine the variable consideration under the expected value method as part of determining the sales transaction price using historical reimbursement experience, historical sales returns, and other operating trends.

In most cases, we record revenue gross, as we are the primary obligor. When we act as an agent in a sales arrangement and do not bear a significant portion of inventory risks, primarily for our outsourced logistics business, we record revenue net of product cost. Sales taxes collected from customers and remitted to governmental authorities are excluded from revenues.

Within our Patient Direct segment, revenues are recognized under fee-for-service arrangements for equipment we rent to patients and sales of equipment, supplies and other items we sell to patients. Revenue that is generated from equipment that we rent to patients is primarily recognized over the noncancelable rental period, typically one month, and commences on delivery of the equipment to the patients. Revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including private insurers, prepaid health plans, Medicare, Medicaid and patients. Rental revenue, less estimated adjustments, is recognized as earned on a straight-line basis over the noncancellable lease term. We recorded $148 million and $299 million in revenue related to equipment we rent to patients for the three and nine months ended September 30, 2022. Equipment rental revenue was not material in the prior year.

Note 2—Fair Value

The carrying amounts of cash and cash equivalents, accounts receivable, ~~and~~ accounts payable, and accrued payroll and related liabilities reported in the consolidated balance sheets approximate fair value due to the short-term nature of these instruments. The carrying amount of restricted cash also approximates fair value due to its nature. The fair value of debt is estimated based on quoted market prices or dealer quotes for the identical liability when traded as an asset in an active market (Level 1) or, if quoted market prices or dealer quotes are not available, on the borrowing rates currently available for loans with similar terms, credit ratings, and average remaining maturities (Level 2). See Note 6 for the fair value of debt. The fair value of ~~foreign currency~~our derivative contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. See Note 8 for the fair value of derivatives.

Note 3—Acquisition

On March 29, 2022 (the Acquisition Date), we completed the acquisition of 100% of Apria, Inc. (Apria) pursuant to the Agreement and Plan of Merger (Apria Acquisition) dated January 7, 2022, in exchange for approximately $1.7 billion, net of $144 million of cash acquired. The purchase was funded with a combination of debt and cash on hand. At the time of the Apria Acquisition, each share of Apria’s common stock was converted into the right to receive $37.50 in cash. Apria is a leading provider of integrated home healthcare equipment and related services in the United States. This business is reported as part of the Patient Direct segment.

The following table presents the preliminary estimated fair value of the assets acquired and liabilities assumed recognized as of the Acquisition Date. The fair value and useful lives of tangible and intangible assets acquired have been

Table of Contents

~~Note 3—Discontinued Operations~~estimated based on various valuation methods, including the income and cost approach, using several significant unobservable inputs including, but not limited to projected cash flows and a discount rate. These inputs are considered Level 3 inputs. The allocation of purchase price to assets and liabilities acquired is not yet complete, as valuations of tangible and intangible assets and liabilities are still in process. The updated preliminary purchase price allocation resulted in an approximate $8.3 million reduction in intangible amortization expense during the three months ended September 30, 2022 that would have been recognized in previous periods if the adjustment to provisional amounts were recognized as of the Acquisition Date. This reduction resulted from a reallocation of intangible assets value to those with longer useful lives as compared to the purchase price allocation originally estimated as of the Acquisition Date.


	Preliminary Fair Value Originally Estimated as of Acquisition Date(1)		Differences Between Prior and the Current Periods Preliminary Fair Value Estimate		Preliminary Fair Value Currently Estimated as of Acquisition Date
Assets acquired:
Current assets	$	142,136	$	(1,968)	$	140,168
Goodwill	1,267,079		(17,601)		1,249,478
Intangible assets	295,466		17,334		312,800
Other non-current assets	371,320		(11,149)		360,171
Total assets	$	2,076,001	$	(13,384)	$	2,062,617
Liabilities assumed:
Current liabilities	$	241,266	$	5,012	$	246,278
Noncurrent liabilities	150,128		(18,396)		131,732
Total liabilities	391,394		(13,384)		378,010
Fair value of net assets acquired, net of cash	$	1,684,607	$	—	$	1,684,607

On June 18, 2020, we completed the divestiture of our European logistics business, Movianto (the Divestiture), as well as certain support functions in our Dublin office, to Walden Group SAS (the Buyer) and EHDH (as Buyer’s guarantor) for cash consideration of $133 million. We concluded that the Movianto business met the criteria for discontinued operations through the Divestiture Date, as the intention to sell represented a strategic shift and the criteria for held-for-sale were met. Movianto was(1) As previously reported in our first quarter 2022 Form 10-Q.

Current assets acquired includes $89.3 million in fair value of receivables, which reflects the ~~Global Solutions segment.~~approximate amount contractually owed. We are amortizing the preliminary fair value of acquired intangible assets, primarily customer relationships, including payor and capitated relationships, and trade names over their estimated weighted average useful lives of one to 15 years.

~~Accordingly,~~Goodwill of $1.2 billion, which we assigned to our Patient Direct segment, consists largely of expected opportunities to expand into new markets and further develop a presence in the home healthcare business. Approximately $32 million of the goodwill is expected to be deductible for income tax purposes.

The following table provides pro forma results of ~~operations from the Movianto business are reported in the accompanying consolidated statements of operations as Loss from discontinued operations,~~ net ~~of tax~~revenue and net (loss) income for the three and nine months ended September 30, ~~2020.~~2022 and 2021 as if Apria was acquired on January 1, 2021. The pro forma results below are not necessarily indicative of the results that would have been if the acquisition had occurred on the dates indicated, nor are the pro forma results indicative of results which may occur in the future.

~~The following table summarizes the financial results of our discontinued operations for the three and nine months ended September 30, 2020:~~


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Net revenue	$	2,497,401	$	2,789,372	$	7,681,481	$	8,166,919
Net income (loss)	$	12,497	$	66,935	$	(39,696)	$	227,540

~~Three Months Ended September 30, 2020~~

~~Nine Months Ended September 30, 2020~~

~~Net revenue~~

—

~~226,759~~

~~Cost of goods sold~~

—

~~53,923~~

~~Gross margin~~

—

~~172,836~~

~~Distribution, selling, and administrative expenses~~

—

~~157,512~~

~~Loss on divestiture~~

—

~~65,472~~

~~Acquisition-related and exit and realignment charges~~

—

~~4,825~~

~~Other operating income, net~~

—

~~(388)~~

~~Operating loss~~

—

~~(54,585)~~

~~Interest expense, net~~

—

~~3,144~~

~~Loss from discontinued operations before income taxes~~

—

~~(57,729)~~

~~Income tax provision from discontinued operations~~

—

~~474~~

~~Loss from discontinued operations, net of tax~~

—

~~(58,203)~~

~~We suspended depreciation and amortization on assets that are held-for-sale, including right-of-use assets recorded in accordance with ASU No. 2016-02,~~Pro forma net loss of $39.7 million for the nine months ended September 30, ~~2020.~~

~~No revenue or~~2022 includes pro forma adjustments for interest expense ~~have been recorded~~of $20.8 million and amortization of intangible assets of $10.9 million, which reflects the updated preliminary purchase price allocation. The pro forma net loss also includes $39.4 million in ~~discontinued operations related~~seller transaction expenses and stock compensation expense associated with $108 million owed to the ~~disposal group subsequent to~~holders of Apria stock awards in connection with the ~~Divestiture Date.~~

~~We have entered into transition services agreements with a subsidiary~~Apria Acquisition.Revenue and net income of Apria since the ~~Buyer, pursuant to which we and a subsidiary of the Buyer will provide to each other various transitional services. Certain transition service arrangement costs and reimbursements were recorded during~~Acquisition Date for the three months ended September 30, 2022 included in the consolidated statement of operations were $310 million and $0.7 million, respectively.Revenue and net loss of Apria since the Acquisition Date included in the consolidated statement of operations for the nine months ended September 30, ~~2021~~2022 were $620 million and ~~2020 and were immaterial for the periods presented. These arrangements were substantially completed as of September 30, 2021.~~

~~We had no assets and liabilities of the discontinued Movianto business reflected on the consolidated balance sheets at September 30, 2021 and December 31, 2020.~~

~~The following table provides operating and investing cash flow information for our discontinued operations:~~

$38.4 million, respectively.


	~~Nine Months Ended September 30, 2020~~
~~Operating Activities:~~
~~Loss on divestiture~~	$	~~65,472~~
~~Investing Activities:~~
~~Capital expenditures~~	~~3,027~~

910

Table of Contents

Note 4—Goodwill and Intangible Assets

In connection with our new segment structure, which began in the first quarter of 2022, goodwill is now reported as part of Products & Healthcare Services or Patient Direct. There was no change to our underlying reporting units as part of that segment change and therefore no reallocation of goodwill. The following table summarizes the goodwill balances by segment and the changes in the carrying amount of goodwill through September 30, ~~2021:~~2022:

Global Solutions Global Products Consolidated
Carrying amount of goodwill, December 31, 2020 $ 283,905 $ 110,181 $ 394,086
Currency translation adjustments — (7,393) (7,393)
Carrying amount of goodwill, September 30, 2021 $ 283,905 $ 102,788 $ 386,693


	Products & Healthcare Services		Patient Direct		Consolidated
Carrying amount of goodwill, December 31, 2021	$	106,280	$	283,905	$	390,185
Acquisitions	(532)		1,249,478		1,248,946
Currency translation adjustments	(7,795)		—		(7,795)
Carrying amount of goodwill, September 30, 2022	$	97,953	$	1,533,383	$	1,631,336

Intangible assets subject to amortization at September 30, ~~2021~~2022 and December 31, ~~2020~~2021 were as follows:


		September 30, 2021						December 31, 2020							September 30, 2022							December 31, 2021
		Customer Relationships		Tradenames		Other Intangibles		Customer Relationships		Tradenames		Other Intangibles				Customer Relationships		Tradenames		Other Intangibles			Customer Relationships		Tradenames		Other Intangibles
Gross intangible assets	Gross intangible assets	$	265,527	$	90,000	$	43,313	$	270,505	$	90,000	$	43,245	Gross intangible assets		$	434,582	$	202,000	$	79,062		$	275,526	$	90,000	$	43,189
Accumulated amortization	Accumulated amortization	(139,632)		(31,152)		(18,267)		(121,209)		(24,881)		(14,309)		Accumulated amortization		(182,741)		(45,203)		(23,623)			(146,168)		(33,242)		(19,560)
Net intangible assets	Net intangible assets	$	125,895	$	58,848	$	25,046	$	149,296	$	65,119	$	28,936	Net intangible assets		$	251,841	$	156,797	$	55,439		$	129,358	$	56,758	$	23,629
Weighted average useful life	Weighted average useful life	10 years		11 years		8 years		10 years		11 years		8 years		Weighted average useful life		12 years		10 years		7 years			10 years		11 years		8 years

At September 30, 2022 and December 31, 2021, ~~$51.1~~$142 million and $164 million in net intangible assets were held in the ~~Global Solutions~~Products & Healthcare Services segment and ~~$159~~$322 million and $45.7 million were held in the ~~Global Products~~Patient Direct segment. Amortization expense for intangible assets was ~~$10.0~~$14.3 million and ~~$10.2~~$10.0 million for the three months ended September 30, 2022 and 2021 and ~~2020,~~$55.5 million and $30.1 ~~million and $31.5~~ million for the nine months ended September 30, ~~2021~~2022 and ~~2020.~~2021. At September 30, 2022, customer relationships, tradenames, and other intangibles include preliminary estimated fair values of assets acquired as part of the Apria Acquisition.

Based on the current carrying value of intangible assets subject to amortization, estimated amortization expense is approximately ~~$10~~$22 million for the remainder of ~~2021, $39 million for~~ 2022, ~~$39~~$82 million for 2023, ~~$34~~$65 million for 2024, ~~$28~~$55 million for 2025, ~~and $27~~$54 million for ~~2026.~~2026 and $47 million for 2027.

Note 5—Exit and Realignment Costs

We periodically incur exit and realignment and other charges associated with optimizing our operations which includes the consolidation of certain distribution and outsourced logistics centers, administrative offices and warehouses, our client engagement center and IT restructuring charges. These charges also include costs associated with our strategic organizational realignment which include leadership reorganization costs, certain professional fees, ~~and~~ costs to streamline administrative functions and processes and divestiture related costs.

Exit and realignment charges by segment for the three and nine months ended September 30, ~~2021~~2022 and ~~2020~~2021 were as follows:

Three Months Ended
September 30, Nine Months Ended September 30,
2021 2020 2021 2020
Global Solutions segment $ 5,352 $ 2,714 $ 16,166 $ 6,255
Global Products segment 1,028 2,877 4,801 3,364
Total exit and realignment charges $ 6,380 $ 5,591 $ 20,967 $ 9,619


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Products & Healthcare Services	$	1,983	$	5,091	$	4,396	$	18,933
Patient Direct	—		1,289		483		2,034
Total exit and realignment charges	$	1,983	$	6,380	$	4,879	$	20,967

1011

Table of Contents

The following table summarizes the activity related to exit and realignment cost accruals through September 30, ~~2021~~2022 and ~~2020:~~

2021:


	Total
Accrued exit and realignment costs, December 31, 2021	$	8,306
Provision for exit and realignment activities:
Severance	811
Other	871
Cash payments	(6,903)
Accrued exit and realignment costs, March 31, 2022	3,085
Provision for exit and realignment activities:
Severance	246
Other	968
Cash payments	(3,477)
Accrued exit and realignment costs, June 30, 2022	822
Provision for exit and realignment activities:
Other	1,251
Cash payments	(1,693)
Accrued exit and realignment costs, September 30, 2022	$	380

Accrued exit and realignment costs, December 31, 2020	$	3,146
Provision for exit and realignment activities:
Information system restructuring costs	1,029
Lease obligations	347
Other	781
Cash payments	(2,915)
Accrued exit and realignment costs, March 31, 2021	2,388
Provision for exit and realignment activities:
Information system restructuring costs	1,611
Lease obligations	(126)
Other	989
Cash payments	(2,302)
Accrued exit and realignment costs, June 30, 2021	2,560
Provision for exit and realignment activities:
Information system restructuring costs	1,506
Lease obligations	107
Other	3,142
Cash payments	(4,199)
Accrued exit and realignment costs, September 30, 2021	$	3,116

~~Accrued exit and realignment costs, December 31, 2019~~	$	~~8,162~~
~~Provision for exit and realignment activities:~~
~~Severance~~	~~1,391~~
~~Information system restructuring costs~~	~~183~~
~~Lease obligations~~	~~202~~
~~Other~~	53
~~Cash payments~~	~~(5,799)~~
~~Accrued exit and realignment costs, March 31, 2020~~	~~4,192~~
~~Provision for exit and realignment activities:~~
~~Severance~~	~~809~~
~~Information system restructuring costs~~	~~671~~
~~Lease obligations~~	~~219~~
~~Other~~	~~501~~
~~Cash payments~~	~~(2,072)~~
~~Accrued exit and realignment costs, June 30, 2020~~	~~4,320~~
~~Provision for exit and realignment activities:~~
~~Severance~~	~~1,950~~
~~Information system restructuring costs~~	77
~~Lease obligations~~	~~848~~
~~Other~~	~~2,716~~
~~Cash payments~~	~~(7,083)~~
~~Accrued exit and realignment costs, September 30, 2020~~	$	~~2,828~~

~~Table of Contents~~

In addition to the exit and realignment accruals in the preceding table, we also incurred $0.7 million of costs that were expensed as incurred for the three and nine months ended September 30, 2022, which related to an increase in reserves associated with certain retained assets of Fusion5. We incurred $1.6 million and $11.6 million of costs that were expensed as incurred for the three and nine months ended September 30, 2021, which primarily includes $1.5 million and $9.6 million of wind-down costs related to Fusion5 for the three and nine months ended September 30, 2021.

Table of Contents

Acquisition-related charges within acquisition-related and exit and realignment charges presented in our consolidated statements of operations were $6.9 million and $45.2 million for the three and nine months ended September 30, 2022, which consisted primarily of costs related to the Apria Acquisition. There were no acquisition-related charges included within acquisition-related and exit and realignment charges presented in our consolidated statements of operations for the three and nine months ended September 30, 2021. ~~Acquisition-related charges within acquisition-related and exit and realignment charges presented~~

We do not expect material additional costs in ~~our consolidated statements of operations~~2022 for activities that were ~~$0.8 million and $8.9 million for the three and nine months ended~~initiated through September 30, ~~2020, which consisted primarily of transition costs for the Halyard acquisition.~~

~~We may incur additional charges in 2021 for wind-down costs related to Fusion5.~~2022.

Note 6—Debt

Debt consists of the following:


		September 30, 2021				December 31, 2020					September 30, 2022				December 31, 2021
		Carrying Amount		Estimated Fair Value		Carrying Amount		Estimated Fair Value			Carrying Amount		Estimated Fair Value		Carrying Amount		Estimated Fair Value
Term Loan A-2		$	—	$	—	$	33,865	$	34,390
Receivables securitization program										Receivables securitization program	$	153,823	$	157,000	$	197,026	$	200,000
4.375% Senior Notes, due December 2024										4.375% Senior Notes, due December 2024	245,436		239,179		245,086		263,263
Term Loan A										Term Loan A	490,278		500,000		—		—
4.500% Senior Notes, due March 2029										4.500% Senior Notes, due March 2029	492,469		394,855		491,656		515,225
Term Loan B	Term Loan B	—		—		477,525		486,614		Term Loan B	577,062		585,806		—		—
Receivables Securitization Program		196,683		200,000		152,929		155,100
4.375% Senior Notes, due December 2024		245,011		261,329		244,780		253,241
Revolver		12,300		12,300		103,200		103,200
4.500% Senior Notes, due March 2029		491,430		507,075		—		—
6.625% Senior Notes, due April 2030										6.625% Senior Notes, due April 2030	584,934		526,968		—		—
Finance leases and other	Finance leases and other	15,677		15,677		13,668		13,668		Finance leases and other	17,777		17,777		15,809		15,809
Total debt	Total debt	961,101		996,381		1,025,967		1,046,213		Total debt	2,561,779		2,421,585		949,577		994,297
Less current maturities	Less current maturities	(1,616)		(1,616)		(39,949)		(40,453)		Less current maturities	(14,720)		(14,720)		(2,037)		(2,037)
Long-term debt	Long-term debt	$	959,485	$	994,765	$	986,018	$	1,005,760	Long-term debt	$	2,547,059	$	2,406,865	$	947,540	$	992,260

We have $246 million, excluding deferred financing costs and third party fees, of 4.375% senior notes due in December 2024 (the 2024 Notes), with interest payable semi-annually. The 2024 Notes were sold at 99.6% of the principal amount with an effective yield of 4.422%. We have the option to redeem the 2024 Notes in part or in whole prior to maturity at a redemption price equal to the greater of 100% of the principal amount or the present value of the remaining scheduled payments discounted at the applicable Benchmark Treasury Rate (as defined) plus 30 basis points.

In March 2021, we issued $500 million, excluding deferred financing costs and third party fees, of 4.500% senior unsecured notes due in March 2029 (the 2029 Unsecured Notes), with interest payable semi-annually (the Notes Offering). The 2029 Unsecured Notes were sold at 100% of the principal amount with an effective yield of 4.500%. We used a portion of the net proceeds from the Notes Offering to repay our Term B Loan and borrowings under our revolving credit facility. In connection with these repayments, we recorded $15.3 million in write-offs of deferred financing costs and third party fees within loss on extinguishment of debt for the nine months ended September 30, 2021. No write-offs of deferred financing costs and third party fees were recorded for the three months ended September 30, 2021. We may redeem all or part of the 2029 Unsecured Notes prior to March 31, 2024, at a price equal to 100% of the principal amount of the 2029 Unsecured Notes redeemed, plus accrued and unpaid interest, if any, to, but not including, the redemption date, plus a “make-whole” premium, as described in the Indenture dated March 10, 2021 (the Indenture). On or after March 31, 2024, we may redeem all or part of the 2029 Unsecured Notes at the applicable redemption prices described in the Indenture, plus accrued and unpaid interest, if any, to, but not including, the redemption date. We may also redeem up to 40% of the aggregate principal amount of the 2029 Unsecured Notes at any time prior to March 31, 2024, at a redemption price equal to 104.5% with an amount equal to or less than the net cash proceeds from certain equity offerings, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

On March ~~10, 2021,~~29, 2022, we ~~terminated~~completed the sale of $600 million in aggregate principal amount of our ~~then existing credit agreement~~6.625% senior notes due in April 2030 (the 2030 Unsecured Notes), with interest payable semi-annually. The 2030 Unsecured Notes were sold at 100% of the principal amount with an effective yield of 6.625%. We may redeem all or part of the 2030 Unsecured Notes, prior to April 1, 2025, at a price equal to 100% of the principal amount of the 2030 Unsecured Notes to be redeemed, plus accrued and ~~all obligations thereunder were repaid. On that same~~unpaid interest, if any, to, but excluding, the redemption date, ~~we entered into~~plus a new credit agreement with Bank of America, N.A. and a syndicate of lenders (the Credit Agreement) with a $300 million revolving credit facility. The interest rate on our revolving credit facility is based on a spread over a benchmark rate (as“make-whole” premium, as described in the ~~Credit Agreement)~~Indenture dated March 29, 2022 (the New Indenture). From and after April 1, 2025, we may redeem all or part of the 2030 Unsecured Notes at the applicable redemption prices described in the New Indenture, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. We may also redeem up to 40% of the aggregate principal amount of 2030 Unsecured Notes at any time prior to April 1, 2025, at a redemption price equal to 106.625% with an amount equal to or less than the net cash proceeds from certain equity offerings, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.

The ~~Credit Agreement matures in March 2026.~~

~~At September 30, 2021~~2029 Unsecured Notes and ~~December 31, 2020, we had borrowings~~2030 Unsecured Notes are effectively subordinated to any of ~~$12.3 million and $103 million and letters of credit of $9.4 million and $13.9 million outstanding~~our secured indebtedness, including indebtedness under our ~~revolving~~ credit ~~facilities. At September 30, 2021 and December~~agreements.

1213

Table of Contents

~~31, 2020,~~On March 29, 2022, we entered into a term loan credit agreement with an administrative agent and collateral agent and a syndicate of financial institutions, as lenders (the Credit Agreement) that provides for two new credit facilities (i) a $500 million Term Loan A facility (the Term Loan A), and (ii) a $600 million Term Loan B facility (the Term Loan B). The interest rate on the Term Loan A is based on either the Term SOFR or the Base Rate plus an Applicable Rate which varies depending on the current Debt Ratings or Total Leverage Ratio, determined as to whichever shall result in more favorable pricing to the Borrowers (each as defined in the Credit Agreement). The interest rate on the Term Loan B is based on either the Term SOFR or the Base Rate plus an Applicable Rate. The Term Loan A will mature in March 2027 and the Term Loan B will mature in March 2029.

On March 29, 2022, we entered into an amendment to our revolving credit agreement, dated as of March 10, 2021 with an administrative agent and collateral agent and a syndicate of financial institutions, as lenders (Revolving Credit Agreement). The amendment (i) increased the aggregate revolving credit commitments under the Revolving Credit Agreement by $150 million, to an aggregate amount of $450 million and (ii) replaced the Eurocurrency Rate with the Adjusted Term SOFR Rate (each as defined in the Revolving Credit Agreement). The Revolving Credit Agreement matures in March 2027.

At September 30, 2022, we had ~~$278~~no borrowings and letters of credit of $27.9 million under our Revolving Credit Agreement. At December 31, 2021, we had no borrowings and letters of credit of $9.4 million outstanding under our Revolving Credit Agreement. At September 30, 2022 and December 31, 2021, we had $422 million and ~~$283~~$291 million available for ~~borrowing.~~borrowing under our Revolving Credit Agreement. We also had letters of credit and bank guarantees, ~~outstanding~~which were issued outside of the Revolving Credit Agreement for ~~$2.2~~$2.3 million and ~~$1.6~~$2.2 million as of September 30, ~~2021~~2022 and December 31, ~~2020,~~2021, which supports certain leased facilities as well as other normal business activities in the United States and Europe. ~~These letters of credit and guarantees were issued outside of the revolving credit facility.~~

WeOn March 29, 2022, we entered into a Security Agreement Supplement pursuant to which the Security and Pledge Agreement (the Security Agreement), dated March 10, 2021 ~~pursuant~~was supplemented to ~~which we granted~~grant collateral on behalf of the holders of the 2024 Notes, and the parties secured under the ~~Credit Agreement~~credit agreements (the Secured Parties) including first priority liens and security interests in (a) all present and future shares of capital stock owned by the ~~Credit Parties~~Grantors (as ~~defined)~~defined in the ~~Credit Parties’~~Security Agreement) in the Grantors’ present and future subsidiaries, subject to certain customary exceptions, and (b) all present and future personal property and assets of the ~~Credit Parties,~~Grantors, subject to certain exceptions.

On March ~~10, 2021,~~29, 2022, we entered into an amendment to our accounts receivable securitization program (the Receivables ~~Securitization Program)~~Financing Agreement). Pursuant to the amended Receivables ~~Securitization Program,~~Financing Agreement, the aggregate principal amount of the loans made by the Lenders (as defined) will not exceed $450 million outstanding at any time. The interest rate under the Receivables ~~Securitization Program~~Financing Agreement is based on a spread over a benchmark SOFR rate (as described in the ~~Third~~Fourth Amendment to the Receivables Financing Agreement). Under the Receivables ~~Securitization Program,~~Financing Agreement, certain of our subsidiaries sell substantially all of their accounts receivable balances to our wholly owned special purpose entity, O&M Funding LLC. The Receivables ~~Securitization Program~~Financing Agreement matures in March ~~2024.~~2025.

The Revolving Credit Agreement, Term Loan A, Term Loan B, Receivables ~~Securitization Program,~~Financing Agreement, 2024 Notes, 2029 Unsecured Notes, and ~~2029~~2030 Unsecured Notes contain cross-default provisions which could result in the acceleration of payments due in the event of default of any of the related agreements. The terms of the ~~Credit Agreement~~credit agreements also require us to maintain ratios for leverage and interest coverage, including on a pro forma basis in the event of an acquisition or divestiture. We were in compliance with our debt covenants at September 30, ~~2021.~~2022.

As of September 30, ~~2021,~~2022, scheduled future principal payments of debt, excluding finance leases and other, were ~~$446~~$1.5 million in 2022, $15.4 million in 2023, $274 million in 2024, ~~$12.3~~of which $254 million is due in December 2024, $197 million in 2025, $43.5 million in 2026, ~~and $500~~$403 million in ~~2029.~~2027, $6.0 million in 2028, $1.1 billion in 2029, and $600 million in 2030. Current maturities at September 30, ~~2021~~2022 include ~~$1.6~~$6.3 million in principal payments on our Term Loan A, $6.0 million in principal payments on our Term Loan B and $2.5 million in current portion of finance leases.

Table of Contents

Note 7—Retirement Plans

We have a frozen noncontributory, unfunded retirement plan for certain retirees in the United ~~States.~~States (U.S. Retirement Plan). As of September 30, 2022 and December 31, 2021, the accumulated benefit obligation of the U.S. Retirement Plan was $48.3 million and $50.2 million. Certain of our foreign subsidiaries also have defined benefit pension plans covering substantially all of their respective teammates.

The components of net periodic benefit cost for the three and nine months ended September 30, ~~2021~~2022 and ~~2020~~2021 were as follows:


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2021		2020		2021		2020			2022		2021		2022		2021
Service cost	Service cost	$	693	$	362	$	2,106	$	1,073	Service cost	$	603	$	693	$	1,853	$	2,106
Interest cost	Interest cost	443		498		1,337		1,488		Interest cost	516		443		1,559		1,337
Recognized net actuarial loss	Recognized net actuarial loss	353		214		1,060		642		Recognized net actuarial loss	267		353		801		1,060
Net periodic benefit cost	Net periodic benefit cost	$	1,489	$	1,074	$	4,503	$	3,203	Net periodic benefit cost	$	1,386	$	1,489	$	4,213	$	4,503

Note 8—Derivatives

We are directly and indirectly affected by changes in foreign currency, which may adversely impact our financial performance and are referred to as “market risks.” When deemed appropriate, we use derivatives as a risk management tool to mitigate the potential impact of certain market risks. We do not enter into derivative financial instruments for trading purposes.

We enter into foreign currency contracts to manage our foreign exchange exposure related to certain balance sheet items that do not meet the requirements for hedge accounting. These derivative instruments are adjusted to fair value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability.

We pay interest on our Credit Agreement which fluctuates based on changes in our benchmark interest rates. In order to mitigate the risk of increases in benchmark rates, we entered into an interest rate swap agreement whereby we agree to exchange with the counterparty, at specified intervals, the difference between fixed and variable amounts calculated by reference to the notional amount. The interest rate swaps were designated as cash flow hedges. Cash flows related to the interest rate swap agreement are included in interest expense.

We determine the fair value of our foreign currency derivatives and interest rate swaps based on observable market-based inputs or unobservable inputs that are corroborated by market data. We do not view the fair value of our derivatives in isolation, but rather in relation to the fair values or cash flows of the underlying exposure. All derivatives are carried at fair value in our consolidated balance ~~sheets in other current assets and other current liabilities.~~sheets. We consider the risk of counterparty default to be minimal. We report cash flows from our hedging instruments in the same cash flow statement category as the hedged items.

~~Table of Contents~~

The following table summarizes the terms and fair value of our outstanding derivative financial instruments as of September 30, ~~2021:~~2022:

Derivative Assets

Derivative Liabilities

Derivative Assets

Derivative Liabilities

Notional Amount

Maturity Date

Classification

Fair Value

Classification

Fair Value

Notional Amount

Maturity Date

Classification

Fair Value

Classification

Fair Value

Cash flow hedges

Interest rate swaps

400,000

March 2027

Other assets, net

16,123

Other liabilities

—

Economic (non-designated) hedges

Foreign currency contracts

14,400

October 2021

Other current assets

Other current liabilities

—

Foreign currency contracts

54,062

October 2022

Other current assets

Other current liabilities

273

In March 2021, we terminated the remaining $300 million in notional value of interest rate swaps concurrent with the debt financing transaction. ~~In September 2020, we terminated $150 million in notional value of interest rate swaps.~~ The remaining balance of the fair value adjustments of $25.1 million, which related to these

Table of Contents

terminated interest rate swaps, within Accumulated other comprehensive loss was reclassified to Loss on extinguishment of debt within our consolidated statements of operations for the nine months ended September 30, 2021.

The following table summarizes the terms and fair value of our outstanding derivative financial instruments as of December 31, ~~2020:~~2021:

Derivative Assets

Derivative Liabilities

Derivative Assets

Derivative Liabilities

Notional Amount

Maturity Date

Classification

Fair Value

Classification

Fair Value

Notional Amount

Maturity Date

Classification

Fair Value

Classification

Fair Value

Cash flow hedges

Interest rate swaps

300,000

May 2022 and May 2025

Other assets, net

—

Other liabilities

17,872

Economic (non-designated) hedges

Foreign currency contracts

30,300

January 2021

Other current assets

151

Other current liabilities

—

Foreign currency contracts

9,700

January 2022

Other current assets

Other current liabilities

—

The following table summarizes the effect of cash flow hedge accounting on our consolidated statements of operations for the three and nine months ended September 30, ~~2021:~~2022:

Amount of Gain Recognized in Other Comprehensive Income (Loss) Location of Loss Reclassified from Accumulated Other Comprehensive Loss into Income Total Amount of Expense Line Items Presented in the Consolidated Statement of Operations in Which the Effects are Recorded Amount of Loss Reclassified from Accumulated Other Comprehensive Loss into Income
Three Months Ended September 30, 2021 Nine Months Ended September 30, 2021 Three Months Ended September 30, 2021 Nine Months Ended September 30, 2021 Three Months Ended September 30, 2021 Nine Months Ended September 30, 2021
Interest rate swaps $ — $ 2,426 Loss on extinguishment of debt $ — $ (40,433) $ — $ (25,518)

~~The amount of ineffectiveness associated with these contracts was immaterial for the periods presented.~~


	Amount of Gain Recognized in Other Comprehensive Income (Loss)				Location of Loss Reclassified from Accumulated Other Comprehensive Loss into Income	Total Amount of Expense Line Items Presented in the Consolidated Statement of Operations in Which the Effects are Recorded				Amount of Loss Reclassified from Accumulated Other Comprehensive Loss into Income
	Three months ended September 30, 2022		Nine months ended September 30, 2022			Three months ended September 30, 2022		Nine months ended September 30, 2022		Three months ended September 30, 2022		Nine months ended September 30, 2022
Interest rate swaps	$	12,153	$	14,197	Interest expense, net	$	39,869	$	87,727	$	(234)	$	(1,926)

The following table summarizes the effect of cash flow hedge accounting on our consolidated statements of operations for the three and nine months ended September 30, ~~2020:~~2021:

~~Table of Contents~~

Amount of Loss Recognized in Other Comprehensive Income (Loss) Location of Loss Reclassified from Accumulated Other Comprehensive Loss into Income Total Amount of Expense Line Items Presented in the Consolidated Statement of Operations in Which the Effects are Recorded Amount of Loss Reclassified from Accumulated Other Comprehensive Loss into Income
Three Months Ended September 30, 2020 Nine Months Ended September 30, 2020 Three Months Ended September 30, 2020 Nine Months Ended September 30, 2020 Three Months Ended September 30, 2020 Nine Months Ended September 30, 2020
Interest rate swaps $ (515) $ (19,913) Interest expense, net $ (20,975) $ (65,923) $ (3,028) $ (6,889)


	Amount of Gain Recognized in Other Comprehensive Income (Loss)				Location of Loss Reclassified from Accumulated Other Comprehensive Loss into Income	Total Amount of Expense Line Items Presented in the Consolidated Statement of Operations in Which the Effects are Recorded				Amount of Loss Reclassified from Accumulated Other Comprehensive Loss into Income
	Three months ended September 30, 2021		Nine months ended September 30, 2021			Three months ended September 30, 2021		Nine months ended September 30, 2021		Three months ended September 30, 2021		Nine months ended September 30, 2021
Interest rate swaps	$	—	$	2,426	Loss on extinguishment of debt	$	—	$	(40,433)	$	—	$	(25,518)

The amount of ineffectiveness associated with these contracts was immaterial for the periods presented.

For the three and nine months ended September 30, ~~2021~~2022 we recognized losses of ~~$0.9~~$1.8 million and ~~$2.5~~$3.2 million associated with our economic (non-designated) foreign currency contracts. For the three and nine months ended September 30, ~~2020~~2021 we recognized losses of $0.9 million and ~~$2.3~~$2.5 million associated with our economic (non-designated) foreign currency contracts.

We recorded the change in fair value of derivative instruments and the remeasurement adjustment of the foreign currency denominated asset or liability in other operating income, net for our foreign exchange contracts.

Note 9—Leases

Table of Contents

The components of lease expense were as follows:


		Three Months Ended September 30,				Nine Months Ended September 30,
	Classification	2022		2021		2022		2021
Operating lease cost	DS&A Expenses	$	24,231	$	15,307	$	64,832	$	44,098
Finance lease cost:
Amortization of lease assets	DS&A Expenses	318		254		944		675
Interest on lease liabilities	Interest expense, net	304		315		915		916
Total finance lease cost		622		569		1,859		1,591
Short-term lease cost	DS&A Expenses, Cost of goods sold	1,207		225		2,363		708
Variable lease cost	DS&A Expenses, Cost of goods sold	10,390		4,349		24,418		13,009
Total lease cost		$	36,450	$	20,450	$	93,472	$	59,406

Variable lease cost consists of taxes, insurance, and common area or other maintenance costs for our leased facilities and patient services equipment which are paid as incurred. Variable lease cost also includes expense associated with patient services equipment, which is based on equipment usage or a percentage of net revenues collected for specific products. Patient equipment lease expense is recorded in cost of goods sold in the consolidated statement of operations.

Supplemental balance sheet information is as follows:


	Classification	September 30, 2022		December 31, 2021
Assets:
Operating lease assets	Operating lease assets	$	275,833	$	194,006
Finance lease assets	Property and equipment, net	10,754		8,896
Total lease assets		$	286,587	$	202,902
Liabilities:
Current
Operating	Other current liabilities	$	72,990	$	41,817
Finance	Other current liabilities	2,470		2,037
Noncurrent
Operating	Operating lease liabilities, excluding current portion	215,022		162,241
Finance	Long-term debt, excluding current portion	13,023		11,314
Total lease liabilities		$	303,505	$	217,409

The gross value recorded under finance leases was $20.0 million and $20.6 million with associated accumulated depreciation of $9.2 million and $11.7 million as of September 30, 2022 and December 31, 2021. Operating lease assets include $83.6 million in right-of-use assets and $86.8 million of operating lease liabilities associated with Apria as of September 30, 2022.

Table of Contents

Other information related to leases was as follows:


	Nine Months Ended September 30,
	2022		2021
Supplemental cash flow information
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating and finance leases	$	63,488	$	43,687
Financing cash flows from finance leases	$	1,115	$	726

Right-of-use assets obtained in exchange for new operating and finance lease liabilities	$	64,325	$	76,960

Weighted average remaining lease term (years)
Operating leases	4.3		5.2
Finance leases	5.9		6.9

Weighted average discount rate
Operating leases	6.9%		8.6%
Finance leases	10.8%		11.0%

Maturities of lease liabilities as of September 30, 2022 were as follows:


	Operating Leases (1)		Finance Leases		Total
2022	$	24,060	$	675	$	24,735
2023	93,913		2,693		96,606
2024	80,267		2,641		82,908
2025	58,612		2,588		61,200
2026	41,058		2,506		43,564
Thereafter	49,224		4,774		53,998
Total lease payments	347,134		15,877		363,011
Less: Interest	(59,122)		(384)		(59,506)
Present value of lease liabilities	$	288,012	$	15,493	$	303,505

(1) Operating lease payments exclude $40.2 million of legally binding lease payments for the Morgantown, West Virginia center of excellence for medical supplies and logistics lease signed, but not yet commenced.

Note 10—Income Taxes

The effective tax rate was ~~12.6%~~36.2% and ~~20.8%~~24.4% for the three and nine months ended September 30, ~~2021,~~2022, compared to ~~13.8%~~12.6% and ~~9.4%~~20.8% in the same periods of ~~2020.~~2021. The change in these rates resulted primarily from an income tax benefit recorded in the first quarter of 2020 associated with the Coronavirus Aid, Relief, and Economic Security (CARES) Act and in the third quarter of 2021 associated with the 2017 Tax Cuts and Jobs Act, the mixture of income and losses in jurisdictions in which we operate, as well as the utilization of foreign tax benefits in the three and ~~the incremental income tax benefit associated with the vesting of restricted stock.~~nine months ended September 30, 2021. The liability for unrecognized tax benefits was ~~$23.0~~$22.1 million at September 30, ~~2021~~2022 and ~~$20.8~~$21.4 million at December 31, ~~2020.~~2021. Included in the liability at September 30, ~~2021~~2022 and December 31, ~~2020~~2021 were $2.7 million of tax positions for which ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility.

On August 26, 2020, we received a Notice of Proposed Adjustment (NOPA) from the Internal Revenue ~~Services~~Service (IRS) regarding our 2015 and 2016 consolidated income tax returns. On June 30, 2021, we received a NOPA from the IRS regarding our 2017 and 2018 consolidated income tax returns. Within the NOPAs, the IRS has asserted that our taxable income for the aforementioned years should be higher based on their assessment of the appropriate amount of taxable income that we should report in the United States in connection with our sourcing of products by our foreign subsidiaries for sale in the United States by our domestic subsidiaries. Our amount of taxable income in the United States is based on our transfer pricing methodology, which has been consistently applied through the current date. We strongly disagree with the IRS position and will pursue all available administrative and judicial remedies, including those available under the U.S. - Ireland Income Tax Treaty to alleviate double taxation. We regularly assess the likelihood of adverse outcomes resulting from examinations such as this to determine the adequacy of our tax reserves. We believe that we have adequately reserved for this matter and that the final adjudication of

Table of Contents

this matter will not have a material impact on our consolidated financial position, results of operations or cash flows. However, the ultimate outcome of disputes of this nature is uncertain, and if the IRS were to prevail on its assertions, the additional tax, interest, and any potential penalties could have a material adverse impact on our financial position, results of operations or cash flows.

~~Table of Contents~~

Note ~~10—~~11—Net Income ~~(Loss)~~ per Common Share

The following summarizes the calculation of net income ~~(loss)~~ per common share attributable to common shareholders for the three and nine months ended September 30, ~~2021~~2022 and ~~2020:~~2021:

Three Months Ended
September 30, Nine Months Ended
September 30,
(in thousands, except per share data) 2021 2020 2021 2020
Income from continuing operations, net of tax $ 44,129 $ 46,081 $ 179,614 $ 37,332
Loss from discontinued operations, net of tax — — — (58,203)
Net income (loss) $ 44,129 $ 46,081 $ 179,614 $ (20,871)
Weighted average shares outstanding - basic 73,215 60,786 72,649 60,983
Dilutive shares 2,743 137 2,754 —
Weighted average shares outstanding - diluted 75,958 60,923 75,403 60,983
Basic income (loss) per common share:
Income from continuing operations $ 0.60 $ 0.76 $ 2.47 $ 0.61
Loss from discontinued operations — — — (0.95)
Net income (loss) $ 0.60 $ 0.76 $ 2.47 $ (0.34)
Diluted income (loss) per common share:
Income from continuing operations $ 0.58 $ 0.76 $ 2.38 $ 0.61
Loss from discontinued operations — — — (0.95)
Net income (loss) $ 0.58 $ 0.76 $ 2.38 $ (0.34)


	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands, except per share data)	2022		2021		2022		2021
Net income	$	12,497	$	44,129	$	80,381	$	179,614

Weighted average shares outstanding - basic	74,905		73,215		74,376		72,649
Dilutive shares	1,510		2,743		1,835		2,754
Weighted average shares outstanding - diluted	76,415		75,958		76,211		75,403

Net income per common share:
Basic	$	0.17	$	0.60	$	1.08	$	2.47
Diluted	$	0.16	$	0.58	$	1.05	$	2.38

Note ~~11—~~12—Shareholders' Equity

In May 2020, we entered into an equity distribution agreement, pursuant to which we may offer and sell, from time to time, shares of our common stock having an aggregate offering price of up to $50.0 million. We intend to use the net proceeds from the sale of our securities offered by this program for the repayment of indebtedness and/or for general corporate and working capital purposes. As of September 30, ~~2021,~~2022, no shares were issued and $50.0 million of common stock remained available under the at-the-market equity financing program.

Note ~~12—~~13—Accumulated Other Comprehensive Loss

The following table shows the changes in accumulated other comprehensive loss by component for the three and nine months ended September 30, ~~2021~~2022 and ~~2020:~~2021:


	Retirement Plans		Currency Translation Adjustments		Derivatives		Total
Accumulated other comprehensive (loss) income, June 30, 2022	$	(14,111)	$	(45,612)	$	2,764	$	(56,959)
Other comprehensive (loss) income before reclassifications	—		(19,986)		12,153		(7,833)
Income tax	—		—		(3,159)		(3,159)
Other comprehensive (loss) income before reclassifications, net of tax	—		(19,986)		8,994		(10,992)
Amounts reclassified from accumulated other comprehensive (loss) income	374		—		234		608
Income tax	(86)		—		(61)		(147)
Amounts reclassified from accumulated other comprehensive (loss) income, net of tax	288		—		173		461
Other comprehensive income (loss)	288		(19,986)		9,167		(10,531)
Accumulated other comprehensive (loss) gain, September 30, 2022	$	(13,823)	$	(65,598)	$	11,931	$	(67,490)

Table of Contents


		Retirement Plans		Currency Translation Adjustments		Derivatives		Total			Retirement Plans		Currency Translation Adjustments		Derivatives		Total
Accumulated other comprehensive loss, June 30, 2021	Accumulated other comprehensive loss, June 30, 2021	$	(18,290)	$	(14,728)	$	—	$	(33,018)	Accumulated other comprehensive loss, June 30, 2021	$	(18,290)	$	(14,728)	$	—	$	(33,018)
Other comprehensive loss before reclassifications	Other comprehensive loss before reclassifications	—		(12,014)		—		(12,014)		Other comprehensive loss before reclassifications	—		(12,014)		—		(12,014)
Income tax	Income tax	—		—		—		—		Income tax	—		—		—		—
Other comprehensive loss before reclassifications, net of tax	Other comprehensive loss before reclassifications, net of tax	—		(12,014)		—		(12,014)		Other comprehensive loss before reclassifications, net of tax	—		(12,014)		—		(12,014)
Amounts reclassified from accumulated other comprehensive loss	Amounts reclassified from accumulated other comprehensive loss	500		—		—		500		Amounts reclassified from accumulated other comprehensive loss	500		—		—		500
Income tax	Income tax	(105)		—		—		(105)		Income tax	(105)		—		—		(105)
Amounts reclassified from accumulated other comprehensive loss, net of tax	Amounts reclassified from accumulated other comprehensive loss, net of tax	395		—		—		395		Amounts reclassified from accumulated other comprehensive loss, net of tax	395		—		—		395
Other comprehensive income (loss)	Other comprehensive income (loss)	395		(12,014)		—		(11,619)		Other comprehensive income (loss)	395		(12,014)		—		(11,619)
Accumulated other comprehensive loss, September 30, 2021	Accumulated other comprehensive loss, September 30, 2021	$	(17,895)	$	(26,742)	$	—	$	(44,637)	Accumulated other comprehensive loss, September 30, 2021	$	(17,895)	$	(26,742)	$	—	$	(44,637)

Retirement Plans Currency Translation Adjustments Derivatives Total
Accumulated other comprehensive loss, June 30, 2020 $ (13,926) $ (23,471) $ (24,188) $ (61,585)
Other comprehensive income (loss) before reclassifications — 5,173 (516) 4,657
Income tax — — 40 40
Other comprehensive income (loss) before reclassifications, net of tax — 5,173 (476) 4,697
Amounts reclassified from accumulated other comprehensive loss 214 — 3,028 3,242
Income tax (47) — (871) (918)
Amounts reclassified from accumulated other comprehensive loss, net of tax 167 — 2,157 2,324
Other comprehensive income 167 5,173 1,681 7,021
Accumulated other comprehensive loss, September 30, 2020 $ (13,759) $ (18,298) $ (22,507) $ (54,564)


	Retirement Plans		Currency Translation Adjustments		Derivatives		Total
Accumulated other comprehensive loss, December 31, 2021	$	(14,597)	$	(25,994)	$	—	$	(40,591)
Other comprehensive (loss) income before reclassifications	—		(39,604)		14,197		(25,407)
Income tax	—		—		(3,691)		(3,691)
Other comprehensive (loss) income before reclassifications, net of tax	—		(39,604)		10,506		(29,098)
Amounts reclassified from accumulated other comprehensive (loss) income	1,009		—		1,926		2,935
Income tax	(235)		—		(501)		(736)
Amounts reclassified from accumulated other comprehensive (loss) income, net of tax	774		—		1,425		2,199
Other comprehensive income (loss)	774		(39,604)		11,931		(26,899)
Accumulated other comprehensive (loss) gain, September 30, 2022	$	(13,823)	$	(65,598)	$	11,931	$	(67,490)

Retirement Plans Currency
Translation
Adjustments Derivatives Total
Accumulated other comprehensive loss, December 31, 2020 $ (18,447) $ (18) $ (20,044) $ (38,509)
Other comprehensive (loss) income before reclassifications — (26,724) 2,426 (24,298)
Income tax — — (611) (611)
Other comprehensive (loss) income before reclassifications, net of tax — (26,724) 1,815 (24,909)
Amounts reclassified from accumulated other comprehensive loss 704 — 25,518 26,222
Income tax (152) — (7,289) (7,441)
Amounts reclassified from accumulated other comprehensive loss, net of tax 552 — 18,229 18,781
Other comprehensive income (loss) 552 (26,724) 20,044 (6,128)
Accumulated other comprehensive loss, September 30, 2021 $ (17,895) $ (26,742) $ — $ (44,637)

~~Table of Contents~~

Retirement Plans Currency Translation Adjustments Derivatives Total
Accumulated other comprehensive loss, December 31, 2019 $ (14,691) $ (25,301) $ (12,715) $ (52,707)
Other comprehensive loss before reclassifications — (8,577) (19,913) (28,490)
Income tax — — 5,113 5,113
Other comprehensive loss before reclassifications, net of tax — (8,577) (14,800) (23,377)
Amounts reclassified from accumulated other comprehensive loss 1,067 15,580 6,889 23,536
Income tax (135) — (1,881) (2,016)
Amounts reclassified from accumulated other comprehensive loss, net of tax 932 15,580 5,008 21,520
Other comprehensive income (loss) 932 7,003 (9,792) (1,857)
Accumulated other comprehensive loss, September 30, 2020 $ (13,759) $ (18,298) $ (22,507) $ (54,564)


	Retirement Plans		Currency Translation Adjustments		Derivatives		Total
Accumulated other comprehensive loss, December 31, 2020	$	(18,447)	$	(18)	$	(20,044)	$	(38,509)
Other comprehensive (loss) income before reclassifications	—		(26,724)		2,426		(24,298)
Income tax	—		—		(611)		(611)
Other comprehensive (loss) income before reclassifications, net of tax	—		(26,724)		1,815		(24,909)
Amounts reclassified from accumulated other comprehensive loss	704		—		25,518		26,222
Income tax	(152)		—		(7,289)		(7,441)
Amounts reclassified from accumulated other comprehensive loss, net of tax	552		—		18,229		18,781
Other comprehensive income (loss)	552		(26,724)		20,044		(6,128)
Accumulated other comprehensive loss, September 30, 2021	$	(17,895)	$	(26,742)	$	—	$	(44,637)

We include amounts reclassified out of accumulated other comprehensive loss related to defined benefit pension plans as a component of net periodic pension cost recorded in Other expense, ~~(income),~~ net.

~~Note 13—Segment Information~~

Table of Contents

Note 14—Segment Information

We periodically evaluate our application of accounting guidance for reportable segments and disclose information about reportable segments based on the way management organizes the enterprise for making operating decisions and assessing performance. We report our business under 2two segments: ~~Global Solutions~~Products & Healthcare Services and ~~Global Products.~~Patient Direct. The ~~Global Solutions~~Products & Healthcare Services segment includes our United States distribution ~~businesses~~business (Medical ~~Distribution and Patient Direct)~~Distribution), outsourced logistics and value-added services ~~business.~~business, and Global Products which manufactures and sources medical surgical products through our production and kitting operations. The Patient Direct segment includes our home healthcare businesses (Byram and Apria).

We evaluate the performance of our segments based on their operating income excluding intangible amortization and acquisition-related and exit and realignment charges that, either as a result of their nature or size, would not be expected to occur as part of our normal business operations on a regular basis.

Segment assets exclude inter-segment account balances as we believe their inclusion would be misleading and not meaningful. ~~We believe all inter-segment sales are at prices that approximate market.~~

The following tables present financial information by segment:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Net revenue:
Products & Healthcare Services	$	1,903,356	$	2,256,295	$	5,964,784	$	6,621,560
Patient Direct	594,045		245,880		1,439,584		696,609
Consolidated net revenue	$	2,497,401	$	2,502,175	$	7,404,368	$	7,318,169

Operating income:
Products & Healthcare Services	$	23,781	$	64,415	$	174,108	$	316,062
Patient Direct	59,666		14,865		127,791		41,434
Intangible amortization	(14,302)		(10,025)		(55,459)		(30,077)
Acquisition-related and exit and realignment charges	(8,898)		(6,380)		(50,048)		(20,967)
Consolidated operating income	$	60,247	$	62,875	$	196,392	$	306,452

Depreciation and amortization:
Products & Healthcare Services	$	19,121	$	18,868	$	57,325	$	56,874
Patient Direct	39,030		3,774		98,113		11,268
Consolidated depreciation and amortization	$	58,151	$	22,642	$	155,438	$	68,142

Capital expenditures:
Products & Healthcare Services	$	9,743	$	13,498	$	38,804	$	31,768
Patient Direct	39,706		446		76,344		857
Consolidated capital expenditures	$	49,449	$	13,944	$	115,148	$	32,625


	September 30, 2022		December 31, 2021
Total assets:
Products & Healthcare Services	$	2,952,570	$	3,012,303
Patient Direct	2,509,242		468,536
Segment assets	5,461,812		3,480,839
Cash and cash equivalents	76,770		55,712
Consolidated total assets	$	5,538,582	$	3,536,551

Table of Contents

Three Months Ended
September 30, Nine Months Ended
September 30,
2021 2020 2021 2020
Net revenue:
Segment net revenue
Global Solutions $ 2,022,919 $ 1,865,182 $ 5,850,007 $ 5,261,415
Global Products 679,067 473,797 2,026,385 1,235,391
Total segment net revenue 2,701,986 2,338,979 7,876,392 6,496,806
Inter-segment revenue
Global Products (199,811) (151,051) (558,223) (378,466)
Total inter-segment revenue (199,811) (151,051) (558,223) (378,466)
Consolidated net revenue $ 2,502,175 $ 2,187,928 $ 7,318,169 $ 6,118,340
Operating income:
Global Solutions $ 20,366 $ 10,972 $ 47,729 $ 8,522
Global Products 51,327 89,923 310,242 160,268
Inter-segment eliminations 7,587 (8,718) (475) (10,322)
Intangible amortization (10,025) (10,242) (30,077) (31,463)
Acquisition-related and exit and realignment charges (6,380) (6,382) (20,967) (18,500)
Consolidated operating income $ 62,875 $ 75,553 $ 306,452 $ 108,505
Depreciation and amortization:
Global Solutions $ 9,951 $ 9,572 $ 29,678 $ 31,273
Global Products 12,691 11,118 38,464 38,221
Consolidated depreciation and amortization $ 22,642 $ 20,690 $ 68,142 $ 69,494
Capital expenditures:
Global Solutions $ 5,752 $ 3,582 $ 14,776 $ 7,545
Global Products 8,192 10,656 17,849 15,808
Discontinued operations — — — 3,027
Consolidated capital expenditures $ 13,944 $ 14,238 $ 32,625 $ 26,380

September 30, 2021 December 31, 2020
Total assets:
Global Solutions $ 2,135,865 $ 2,117,372
Global Products 1,408,495 1,135,209
Segment assets 3,544,360 3,252,581
Cash and cash equivalents 39,759 83,058
Consolidated total assets $ 3,584,119 $ 3,335,639

The following table presents net revenue by geographic area, which were attributed based on the location from which we ship products or provide ~~services.~~services:

~~Table of Contents~~


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended September 30,				Nine Months Ended September 30,
		2021		2020		2021		2020			2022		2021		2022		2021
Net revenue:	Net revenue:									Net revenue:
United States	United States	$	2,380,794	$	2,101,074	$	6,900,222	$	5,872,143	United States	$	2,410,790	$	2,380,794	$	7,049,382	$	6,900,222
International	International	121,381		86,854		417,947		246,197		International	86,611		121,381		354,986		417,947
Consolidated net revenue	Consolidated net revenue	$	2,502,175	$	2,187,928	$	7,318,169	$	6,118,340	Consolidated net revenue	$	2,497,401	$	2,502,175	$	7,404,368	$	7,318,169

Note ~~14—~~15—Recent Accounting Pronouncements

~~In December 2019,~~On June 16, 2016, the FASB issued ASU No. ~~2019-12, Simplifying~~2016-13 Financial Instruments - Credit Losses, Measurement of Credit Losses on Financial Instruments, which changes the ~~Accounting~~way entities measure credit losses for ~~Income Taxes, which simplifies~~most financial assets and certain other instruments that are not measured at fair value through net earnings. This standard will be effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted. We are still evaluating the ~~accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects~~impact the adoption of the current guidance to promote consistency among reporting entities. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. We adopted ASU No. ~~2019-12 effective beginning January 1, 2021. Its adoption did not~~2016-13 will have ~~a material impact~~ on our consolidated financial ~~statements.~~statements and related disclosures; however, we do not expect this to have a material impact. Subsequent to the issuance of ASU No. 2016-13, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments - Credit Losses and ASU No. 2019-05, Financial Instruments - Credit Losses (Topic 326) Targeted Transition Relief. These ASUs do not change the core principle of the guidance in ASU No. 2016-13. Instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard. These ASUs will have the same effective date and transition requirements as ASU No. 2016-13.

In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The amendments are effective for all entities as of March 12, 2020 through December 31, 2022.Our ~~current~~material debt agreements ~~contemplate~~no longer reference LIBOR as a benchmark rate. The transition ~~from LIBOR to another benchmark rate in the event that LIBOR ceases to exist. We do~~did not ~~expect the transition to~~ have a material impact on our consolidated financial statements.

In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements, to improve consistency by amending the FASB Accounting Standards Codification (the Codification) to include all disclosure guidance in the appropriate disclosure sections. This ASU also clarifies application of various provisions in the Codification by amending and adding new headings, cross referencing to other guidance, and refining or correcting terminology. The amendments in this ASU do not change GAAP and, therefore, are not expected to result in a significant change in practice. We adopted ASU No. 2020-10 effective beginning January 1, 2021. Its adoption did not have a material impact on our consolidated financial statements.

~~There~~In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. ASU 2021-08 requires the company acquiring contract assets and contract liabilities obtained in a business combination to recognize and measure them in accordance with ASC 606, Revenue from Contracts with Customers. At the acquisition date, the company acquiring the business should record related revenue, as if it had originated the contract. Before the update such amounts were recognized by the acquiring company at fair value. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted, including in interim periods, for any financial statements that have not yet been ~~no further changes in~~issued. We adopted ASU 2021-08 prospectively, effective beginning January 1, 2022. Its adoption did not have a material impact on our ~~significant~~consolidated financial statements.

In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which requires certain annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting ~~policies from those contained in~~model by analogy. We adopted ASU No. 2021-10 effective beginning January 1, 2022. Its adoption did not have a material impact on our ~~Annual Report on Form 10-K for the year ended December 31, 2020.~~consolidated financial statements.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis describes results of operations and material changes in the financial condition of Owens & Minor, Inc. and its subsidiaries since December 31, ~~2020.~~2021. Trends of a material nature are discussed to the extent known and considered relevant. This discussion should be read in conjunction with the consolidated financial statements,

Table of Contents

related notes thereto, and management’s discussion and analysis of financial condition and results of operations included in our Annual Report on Form 10-K for the year ended December 31, ~~2020.~~2021.

Overview

Owens & Minor, Inc., along with its subsidiaries, (we, us, or our) is a leading global healthcare solutions company. Our business has two distinct segments: Products & Healthcare Services and Patient Direct. Products & Healthcare Services provides distribution, outsourced logistics and value-added services, and manufactures and sources medical surgical products through our production and kitting operations. Patient Direct expands our business along the continuum of care through delivery of disposable medical supplies sold directly to patients and home health agencies and is a leading provider of integrated home healthcare equipment and related services in the United States. Beginning with the quarter ended March 31, 2022, we have reported financial results using this two segment structure and have recast our prior period segment results on the same basis.

On ~~June 18, 2020~~March 29, 2022 (the ~~Divestiture~~Acquisition Date), we completed the ~~divestiture~~acquisition of ~~our European logistics business, Movianto (the Divestiture), as well as certain support functions~~100% of Apria, Inc. (Apria) pursuant to the Agreement and Plan of Merger (Apria Acquisition) dated January 7, 2022, in ~~our Dublin, Ireland office, to Walden Group SAS (the Buyer) and EHDH (as Buyer’s guarantor)~~exchange for approximately $1.7 billion, net of $144 million of cash ~~consideration of $133 million.~~acquired. The ~~Divestiture provides us~~purchase was funded with a ~~greater ability to focus~~combination of debt and cash on ~~and invest in our differentiated products, services and U.S. distribution businesses.~~

~~As a result~~hand. At the time of the ~~Divestiture,~~Apria Acquisition, each share of Apria’s common stock was converted into the ~~results~~right to receive $37.50 in cash. Apria is a leading provider of ~~operations from our Movianto~~integrated home healthcare equipment and related services in the United States. This business ~~are~~is reported as ~~“Loss from discontinued operations, net~~part of ~~tax”~~the Patient Direct segment.

Net income per diluted share was $0.16 and $1.05 for the three and nine months ended September 30, ~~2020. See Note 3, “Discontinued Operations,” of the Notes~~2022 as compared to ~~Consolidated Financial Statements for further information. Unless otherwise indicated, the following information relates to continuing operations.~~

~~Income from continuing operations per diluted share was~~ $0.58 and $2.38 for the three and nine months ended September 30, ~~2021 as compared to $0.76 and $0.61 for the three and nine months ended September 30, 2020. Global Solutions~~2021. Products & Healthcare Services segment operating income was ~~$20.4~~$23.8 million and ~~$47.7~~$174 million for the three and nine months ended September 30, ~~2021,~~2022, compared to ~~$11.0~~$64.4 million and ~~$8.5~~$316 million for the three and nine months ended September 30, ~~2020. These increases~~2021. The decreases were a

~~Table of Contents~~

primarily the result of ~~strong revenue growth, leveraging our fixed costs,~~overall reduced hospital demand, including reliance on stockpiles built up during the COVID-19 pandemic, the reduction of glove cost pass through, and headwinds created by macroeconomic conditions, including inflationary pressures, supply chain issues, and rising interest rates, partially offset by operating ~~efficiencies. Global Products~~efficiencies and productivity gains derived from the Owens & Minor business system and changes in accrued incentive compensation. Patient Direct segment operating income was ~~$51.3~~$59.7 million and ~~$310~~$127.8 million for the three and nine months ended September 30, ~~2021,~~2022, compared to ~~$89.9~~$14.9 million and ~~$160~~$41.4 million for the three and nine months ended September 30, ~~2020.~~2021. The ~~decrease for the three months ended September 30, 2021~~increase was primarily the result of the ~~timing~~inclusion of ~~glove cost pass-through, accelerating inflationary pressures, including commodities, transportation,~~Apria in the Patient Direct segment since the Acquisition Date, strong revenue growth in our Byram business, leveraging our fixed costs, and ~~labor,~~operating efficiencies, partially offset by ~~revenue growth. The increase~~inflationary pressures. Net income per diluted share was unfavorably impacted as compared to the prior year by foreign currency translation in the amount of $0.04 and $0.13 for the three and nine months ended September 30, 2021 was a result of higher personal protective equipment (PPE) sales, favorable timing of cost pass-through on gloves, productivity initiatives, favorable product mix, and improved fixed cost leverage, partially offset by higher commodity prices and rising transportation costs, compared to the prior year.2022.

COVID-19 Update

We ~~are~~continue to closely ~~monitoring~~monitor the impact of the 2019 novel coronavirus (COVID-19), including ~~the related Delta variant,~~its variants and sub-variants, on all aspects of our business, including ~~how it impacts~~ our customers, teammates, suppliers, vendors and distribution channels. We have taken actions to protect our teammates while maintaining business continuity as we respond to the needs from this global pandemic. We will continue to actively monitor the situation and may take further actions that alter our business operations as may be required by federal, state or local authorities or that we determine are in the best interests of our teammates, customers, suppliers and shareholders.

Revenue for the nine months ended September 30, 2021 of $7.3 billion continues to be impacted by COVID-19 and includes the effective response to the ongoing recovery of elective procedures, higher sales of PPE, and pass-through of elevated glove costs.Operating income for the nine months ended September 30, 2021 also benefited from improved productivity and increased manufacturing output related to PPE, favorable product mix and operating efficiencies. In 2020, we expanded our PPE production operations and have taken measures to increase and improve our production such as retooling existing equipment, installing and optimizing new production lines and ramping up our new non-woven fabric machinery. We expect that we will continue servicing our customers' needs related to the heightened demand for our PPE as a result of various factors, including the implementation of new regulations and healthcare protocols calling for increased use of PPE, healthcare professional preference for medical grade PPE, stockpile PPE demand and the creation of new channels for PPE demand in healthcare, non-healthcare and international markets.

In March 2020, under the Defense Production Act (DPA), we were awarded a contract with the U.S. Department of Health and Human Services to produce N-95 respirator masks in an effort to replenish the Strategic National Stockpile. In April 2020, also under the DPA, the U.S. Department of Defense initiated a technology investment agreement with us involving up to $30.0 million of anticipated funding of assets to expand capacity to supply N-95 respirator masks. Through September 30, 2021, substantially all of the anticipated funding had been expended and reimbursed in accordance with this arrangement.

We are unable to predict the timing of the pandemic and the full impact that COVID-19 will have on our future operating results, financial position and cash flows due to numerous variables and continued uncertainties. ~~Travel, transportation,~~Transportation and business operation restrictions arising from virus containment efforts of governments around the world have continued to impact our operations in certain locations, including within Asia. Essential activity exceptions from these restrictions have allowed us to continue to operate, but virus containment efforts have ~~resulted~~created supply chain challenges resulting in additional direct ~~costs from supply chain challenges.~~costs. Although we have experienced growth in sales volumes for certain of our products (such as ~~PPE)~~personal protective equipment (PPE)) during the COVID-19 pandemic, as well as improved productivity and manufacturing output, there can be no assurance that such growth rates, increased sales volumes or other improvements will be maintained during or following the COVID-19 pandemic.

~~Results of Operations~~

~~Net revenue.~~Philips Respironics Recall

Three Months Ended
September 30, Change
(Dollars in thousands) 2021 2020 $ %
Global Solutions $ 2,022,919 $ 1,865,182 $ 157,737 8.5 %
Global Products 679,067 473,797 205,270 43.3 %
Inter-segment (199,811) (151,051) (48,760) (32.3) %
Net revenue $ 2,502,175 $ 2,187,928 $ 314,247 14.4 %

In June 2021, one of Apria's suppliers, Philips Respironics, announced a voluntary recall (Recall) for continuous and non-continuous ventilators (certain continuous positive airway pressure (CPAP), BiLevel positive airway pressure and ventilator devices) related to polyurethane foam used in those devices. The Food and Drug Administration (FDA) has since identified this as a Class I recall, the most serious category of recall. Because we distribute these products and provide related home respiratory services and, in part, due to the substantial number of impacted devices, we will likely devote substantial time

2123

Table of Contents

Nine Months Ended
September 30, Change
(Dollars in thousands) 2021 2020 $ %
Global Solutions $ 5,850,007 $ 5,261,415 $ 588,592 11.2 %
Global Products 2,026,385 1,235,391 790,994 64.0 %
Inter-segment (558,223) (378,466) (179,757) (47.5) %
Net revenue $ 7,318,169 $ 6,118,340 $ 1,199,829 19.6 %
and resources to coordinating Recall-related activity and to supporting our home healthcare patients’ needs. This Recall may cause us to incur significant costs, some or all of which may not be recoverable from the product manufacturer. The Recall may also materially negatively affect our revenues and results of operations as a result of patients not using their impacted devices, current shortages in the availability of both replacement devices for impacted patients and new devices for new patients, patient hesitancy to use respiratory devices generally or other reasons.

We are closely monitoring the impact of the Recall on our business and the uncertainty surrounding the availability and supply of CPAP and ventilators due to the Recall. While the equipment shortage in the industry has begun to ease, we do not know whether that will continue. The Recall or other supply chain disruptions may have a future material adverse effect on our financial condition or results of operations, cash flows and liquidity.

Results of Operations

Net revenue.


	Three Months Ended September 30,				Change
(Dollars in thousands)	2022		2021		$		%
Products & Healthcare Services	$	1,903,356	$	2,256,295	$	(352,939)	(15.6)	%
Patient Direct	594,045		245,880		348,165		141.6	%
Net revenue	$	2,497,401	$	2,502,175	$	(4,774)	(0.2)	%


	Nine Months Ended September 30,				Change
(Dollars in thousands)	2022		2021		$		%
Products & Healthcare Services	$	5,964,784	$	6,621,560	$	(656,776)	(9.9)	%
Patient Direct	1,439,584		696,609		742,975		106.7	%
Net revenue	$	7,404,368	$	7,318,169	$	86,199	1.2	%

The ~~change~~increase in net revenue in our Patient Direct segment for the three and nine months ended September 30, ~~2021 reflected our market share gains,~~2022 was driven by the ~~effective response to the ongoing recovery~~acquisition of ~~elective procedures, higher sales of surgical & infection prevention (S&IP) products, pass-through of elevated glove costs, as well as~~Apria on March 29, 2022 and continued strong performance in our ~~Patient Direct~~Byram business. The decrease in net revenue in our Products & Healthcare Services segment for the three and nine months ended September 30, 2022 reflected overall reduced hospital demand, including reliance on stockpiles and the reduction of glove cost pass through. Foreign currency translation had ~~a favorable~~an unfavorable impact on net revenue of ~~$1.8~~$12.0 million and ~~$23.5~~$33.2 million for the three and nine months ended September 30, ~~2021~~2022 as compared to the prior year.

Cost of goods sold.


		Three Months Ended September 30,				Change					Three Months Ended September 30,				Change
(Dollars in thousands)	(Dollars in thousands)	2021		2020		$		%		(Dollars in thousands)	2022		2021		$		%
Cost of goods sold	Cost of goods sold	$	2,173,336	$	1,843,589	$	329,747	17.9	%	Cost of goods sold	$	1,984,122	$	2,173,336	$	(189,214)	(8.7)	%


		Nine Months Ended September 30,				Change					Nine Months Ended September 30,				Change
(Dollars in thousands)	(Dollars in thousands)	2021		2020		$		%		(Dollars in thousands)	2022		2021		$		%
Cost of goods sold	Cost of goods sold	$	6,146,511	$	5,236,035	$	910,476	17.4	%	Cost of goods sold	$	5,985,136	$	6,146,511	$	(161,375)	(2.6)	%

Cost of goods sold includes the cost of the product (net of supplier incentives and cash discounts) and all costs incurred for shipments of products from manufacturers to our distribution centers for all customer arrangements where we are the primary obligor and bear risk of general and physical inventory loss. These are sometimes referred to as distribution contracts. Cost of goods sold also includes direct and certain indirect labor, depreciation of certain property and equipment, product costs, and material and overhead ~~costs associated with our Global Products segment. There is no cost of goods sold associated with our fee-for-service arrangements.~~costs. Cost of goods sold compared to prior year reflects the inclusion of Apria since the Acquisition Date, changes in sales activity, including ~~sales~~product mix, inflationary pressures, and ~~accelerating inflationary pressures.~~supply chain issues.

~~Gross margin.~~

Three Months Ended
September 30, Change
(Dollars in thousands) 2021 2020 $ %
Gross margin $ 328,839 $ 344,339 $ (15,500) (4.5) %
As a % of net revenue 13.14 % 15.74 %

Nine Months Ended
September 30, Change
(Dollars in thousands) 2021 2020 $ %
Gross margin $ 1,171,658 $ 882,305 $ 289,353 32.8 %
As a % of net revenue 16.01 % 14.42 %

Gross margin decrease in the three months ended September 30, 2021 was driven by the timing of glove cost pass-through and accelerating inflationary pressures, partially offset by revenue growth. Gross margin increase in the nine months ended September 30, 2021 was driven by revenue growth, market dynamics including timing of glove price and cost changes, an overall improved sales mix and operating efficiencies, partially offset by accelerating inflationary pressures. Foreign

2224

Table of Contents

Gross margin.


	Three Months Ended September 30,						Change
(Dollars in thousands)	2022			2021			$		%
Gross margin	$	513,279		$	328,839		$	184,440	56.1	%
As a % of net revenue	20.55		%	13.14		%


	Nine Months Ended September 30,						Change
(Dollars in thousands)	2022			2021			$		%
Gross margin	$	1,419,232		$	1,171,658		$	247,574	21.1	%
As a % of net revenue	19.17		%	16.01		%

Gross margin increase in the three and nine months ended September 30, 2022 was driven by inclusion of Apria in the Patient Direct segment since the Acquisition Date and sales mix, partially offset by overall reduced hospital demand, including reliance on stockpiles, the reduction of glove cost pass through, inflationary pressures, and supply chain issues. Foreign currency translation had an unfavorable impact on gross margin of ~~$6.2~~$6.4 million and ~~$0.8~~$17.3 million for the three and nine months ended September 30, ~~2021~~2022 as compared to the prior year.

Operating expenses.


		Three Months Ended September 30,						Change					Three Months Ended September 30,						Change
(Dollars in thousands)	(Dollars in thousands)	2021			2020			$		%		(Dollars in thousands)	2022			2021			$		%
Distribution, selling and administrative expenses	Distribution, selling and administrative expenses	$	262,457		$	262,538		$	(81)	—	%	Distribution, selling and administrative expenses	$	445,259		$	262,457		$	182,802	69.7	%
As a % of net revenue	As a % of net revenue	10.49		%	12.00		%					As a % of net revenue	17.83		%	10.49		%
Acquisition-related and exit and realignment charges	Acquisition-related and exit and realignment charges	$	6,380		$	6,382		$	(2)	—	%	Acquisition-related and exit and realignment charges	$	8,898		$	6,380		$	2,518	39.5	%
Other operating income, net	Other operating income, net	$	(2,873)		$	(134)		$	(2,739)	(2,044.0)	%	Other operating income, net	$	(1,125)		$	(2,873)		$	1,748	60.8	%


		Nine Months Ended September 30,						Change					Nine Months Ended September 30,						Change
(Dollars in thousands)	(Dollars in thousands)	2021			2020			$		%		(Dollars in thousands)	2022			2021			$		%
Distribution, selling and administrative expenses	Distribution, selling and administrative expenses	$	849,255		$	758,320		$	90,935	12.0	%	Distribution, selling and administrative expenses	$	1,177,812		$	849,255		$	328,557	38.7	%
As a % of net revenue	As a % of net revenue	11.60		%	12.39		%					As a % of net revenue	15.91		%	11.60		%
Acquisition-related and exit and realignment charges	Acquisition-related and exit and realignment charges	$	20,967		$	18,500		$	2,467	13.3	%	Acquisition-related and exit and realignment charges	$	50,048		$	20,967		$	29,081	138.7	%
Other operating income, net	Other operating income, net	$	(5,016)		$	(3,020)		$	(1,996)	(66.1)	%	Other operating income, net	$	(5,020)		$	(5,016)		$	(4)	(0.1)	%

Distribution, selling and administrative (DS&A) expenses include labor and warehousing costs associated with our distribution and outsourced logistics services and all costs associated with our fee-for-service ~~arrangements.~~arrangements in our Products & Healthcare Services segment. Shipping and handling costs are primarily included in DS&A expenses and include costs to store, move, and prepare products for shipment, as well as costs to deliver products to customers.Overall DS&A expenses were affected by ~~revenue growth,~~inclusion of Apria in our results since the Acquisition Date, and inflationary pressures for the three and nine months ended September 30, 2022, partially offset by operating efficiencies and productivity gains derived from the Owens & Minor business system, and changes in accrued incentive ~~compensation, teammate benefits, accelerating inflationary pressures,~~compensation. DS&A expenses also included a favorable impact for foreign currency translation of $1.8 million and ~~operational efficiencies~~$4.2 million for the three and nine months ended September 30, 2022.

Acquisition-related charges were $6.9 million and $45.2 million for the three and nine months ended September 30, 2022 as compared to no acquisition-related charges for the three and nine months ended September 30, 2021. ~~In addition, overall DS&A expenses~~Acquisition-related charges in 2022 consisted primarily of costs related to the Apria Acquisition. Exit and realignment charges were ~~affected by charitable contributions for the nine months ended September 30, 2021. DS&A expenses also included an unfavorable impact for foreign currency translation of $0.1~~$2.0 million and ~~$2.3~~$4.9 million for the three and nine months ended September 30, ~~2021.~~

~~Acquisition-related~~2022, which consisted primarily of wind-down costs related to Fusion5 and ~~exit~~severance and other charges associated with the reorganization of our segments. Exit and realignment charges ~~presented in our consolidated statements of operations of~~were $6.4 million and $21.0 million for the three and nine months ended September 30, 2021 and consisted primarily of wind-down costs related to Fusion5, leadership reorganization costs, IT restructuring charges, and other costs related to the reorganization of the U.S. operations. ~~Acquisition-related charges within acquisition-related and exit and realignment charges presented in our consolidated statements~~

Table of operations were $0.8 million and $8.9 million for the three and nine months ended September 30, 2020, which consisted primarily of transition costs for the Halyard acquisition. Exit and realignment charges were $5.6 million and $9.6 million for the three and nine months ended September 30, 2020 and consisted primarily of severance from reduction in force, post divestiture costs related to the Movianto business, and other costs related to the reorganization of the U.S. commercial, operations and executive teams.Contents

~~The change in other~~Other operating income, net for the three and nine months ended September 30, 2022 and 2021 includes the impact of ~~higher~~ foreign currency transaction ~~gains as compared to the prior year.~~gains.

Interest expense, net.

Three Months Ended
September 30, Change
(Dollars in thousands) 2021 2020 $ %
Interest expense, net $ 11,572 $ 20,975 $ (9,403) (44.8) %
Effective interest rate 4.17 % 5.64 %


	Three Months Ended September 30,						Change
(Dollars in thousands)	2022			2021			$		%
Interest expense, net	$	39,869		$	11,572		$	28,297	244.5	%
Effective interest rate	5.96		%	4.17		%


	Nine Months Ended September 30,						Change
(Dollars in thousands)	2022			2021			$		%
Interest expense, net	$	87,727		$	36,784		$	50,943	138.5	%
Effective interest rate	5.47		%	4.72		%

~~Table of Contents~~

Nine Months Ended
September 30, Change
(Dollars in thousands) 2021 2020 $ %
Interest expense, net $ 36,784 $ 65,923 $ (29,139) (44.2) %
Effective interest rate 4.72 % 6.35 %

Interest expense, net and the effective interest rate for the three and nine months ended September 30, ~~2021~~2022 ~~decreased~~increased primarily due to ~~a reduction of~~the increase in debt ~~and lower~~associated with the Apria Acquisition on March 29, 2022, along with rising market interest rates. See Note 6 in Notes to Consolidated Financial Statements.

Loss on extinguishment of debt.

Three Months Ended
September 30, Change
(Dollars in thousands) 2021 2020 $ %
Loss on extinguishment of debt $ — $ 308 $ (308) (100.0) %


		Nine Months Ended September 30,				Change					Nine Months Ended September 30,				Change
(Dollars in thousands)	(Dollars in thousands)	2021		2020		$		%		(Dollars in thousands)	2022		2021		$		%
Loss on extinguishment of debt	Loss on extinguishment of debt	$	40,433	$	2,580	$	37,853	1,467.2	%	Loss on extinguishment of debt	$	—	$	40,433	$	(40,433)	(100.0)	%

Loss on extinguishment of debt for the nine months ended September 30, 2021 includes the write-off of deferred financing costs and third party fees associated with the debt financing in March 2021 of $15.3 million and amounts reclassified from accumulated other comprehensive loss as a result of the termination of our interest rate swaps of $25.1 million. ~~Loss on extinguishment of debt for the three and~~ ~~nine~~ ~~months ended September 30, 2020~~ ~~primarily includes the write-off of deferred financing costs and third party fees, offset by the gain on extinguishment of debt related to the partial repurchase of our 2021 and 2024 Notes.~~

Other expense, ~~(income),~~ net.


		Three Months Ended September 30,				Change					Three Months Ended September 30,				Change
(Dollars in thousands)	(Dollars in thousands)	2021		2020		$		%		(Dollars in thousands)	2022		2021		$		%
Other expense (income), net		$	799	$	785	$	14	1.8	%
Other expense, net										Other expense, net	$	783	$	799	$	(16)	(2.0)	%


		Nine Months Ended September 30,				Change					Nine Months Ended September 30,				Change
(Dollars in thousands)	(Dollars in thousands)	2021		2020		$		%		(Dollars in thousands)	2022		2021		$		%
Other expense (income), net		$	2,397	$	(1,193)	$	3,590	300.9	%
Other expense, net										Other expense, net	$	2,347	$	2,397	$	(50)	(2.1)	%

Other expense, ~~(income),~~ net for the three and nine months ended September 30, ~~2021~~2022 and ~~2020~~2021 represents interest cost and net actuarial losses related to our retirement plans.~~Other expense (income), net for the~~ ~~nine months ended September 30, 2020 includes a gain from the surrender of company-owned life insurance policies.~~

Income taxes.

Three Months Ended
September 30, Change
(Dollars in thousands) 2021 2020 $ %
Income tax provision $ 6,375 $ 7,404 $ (1,029) (13.9) %
Effective tax rate 12.6 % 13.8 %


	Three Months Ended September 30,						Change
(Dollars in thousands)	2022			2021			$		%
Income tax provision	$	7,098		$	6,375		$	723	11.3	%
Effective tax rate	36.2		%	12.6		%

2426

Table of Contents

Nine Months Ended
September 30, Change
(Dollars in thousands) 2021 2020 $ %
Income tax provision $ 47,224 $ 3,863 $ 43,361 1,122.5 %
Effective tax rate 20.8 % 9.4 %


	Nine Months Ended September 30,						Change
(Dollars in thousands)	2022			2021			$		%
Income tax provision	$	25,937		$	47,224		$	(21,287)	(45.1)	%
Effective tax rate	24.4		%	20.8		%

The change in the effective tax rate for the three and nine months ended September 30, ~~2021~~2022 compared to the same periods in ~~2020~~2021 resulted primarily from an income tax benefit recorded in the first quarter of 2020 associated with the Coronavirus Aid, Relief, and Economic Security (CARES) Act and in the third quarter of 2021 associated with the 2017 Tax Cuts and Jobs Act, the mixture of income and losses in jurisdictions in which we operate, as well as the as the utilization of foreign tax benefits in the three and ~~the incremental income tax benefit associated with the vesting of restricted stock.~~nine months ended September 30, 2021.

Financial Condition, Liquidity and Capital Resources

Financial condition. We monitor operating working capital through days sales outstanding (DSO) and merchandise inventory days. We estimate a hypothetical increase (decrease) in DSO of one day would result in a decrease (increase) in our cash balances, an increase (decrease) in borrowings against our ~~revolving credit facility~~Revolving Credit Agreement (as defined below) or Receivables ~~Securitization Program,~~Financing Agreement (as defined below), or a combination thereof of approximately $27 million.

The majority of our cash and cash equivalents are held in cash depository accounts with major banks in ~~the United States,~~North America, Europe, and Asia. Changes in our working capital can vary in the normal course of business based upon the timing of inventory purchases, collections of accounts receivable, and payments to suppliers.


		September 30, 2021		December 31, 2020				Change							September 30, 2022				December 31, 2021		Change
(Dollars in thousands)	(Dollars in thousands)					$				%		(Dollars in thousands)					$				%
Cash and cash equivalents	Cash and cash equivalents	$	39,759			$	83,058			$	(43,299)			(52.1)			%	Cash and cash equivalents	$	76,770	$	55,712	$	21,058		37.8	%
Accounts receivable, net of allowances	Accounts receivable, net of allowances	$	759,744	$	700,792			$	58,952			8.4	%	Accounts receivable, net of allowances	$	751,970			$	681,564	$	70,406	10.3		%
Consolidated DSO (1)	Consolidated DSO (1)	27.3		26.0										Consolidated DSO (1)	26.9				24.6
Merchandise inventories	Merchandise inventories	$	1,514,387	$	1,233,751			$	280,636			22.7	%	Merchandise inventories	$	1,508,443			$	1,495,972	$	12,471	0.8		%
Inventory days (2)	Inventory days (2)	64.1		57.8										Inventory days (2)	69.9				64.7
Accounts payable	Accounts payable	$	1,118,753	$	1,000,186			$	118,567			11.9	%	Accounts payable	$	1,156,230			$	1,001,959	$	154,271	15.4		%

(1) Based on period end accounts receivable and net revenue for the quarters ended September 30, ~~2021~~2022 and December 31, ~~2020~~2021.

(2) Based on period end merchandise inventories and cost of goods sold for the quarters ended September 30, ~~2021~~2022 and December 31, ~~2020~~

2021.

Liquidity and capital expenditures. The following table summarizes our consolidated statements of cash flows for the nine months ended September 30, ~~2021~~2022 and ~~2020, which relates to continuing operations and discontinued operations:~~2021:


(Dollars in thousands)	(Dollars in thousands)	2021		2020		(Dollars in thousands)	2022		2021
Net cash provided by (used for):	Net cash provided by (used for):					Net cash provided by (used for):
Operating activities	Operating activities	$	73,836	$	268,196	Operating activities	$	238,045	$	73,836
Investing activities	Investing activities	(32,584)		112,830		Investing activities	(1,771,705)		(32,584)
Financing activities	Financing activities	(117,222)		(244,955)		Financing activities	1,560,585		(117,222)
Effect of exchange rate changes	Effect of exchange rate changes	(2,454)		6,721		Effect of exchange rate changes	(5,752)		(2,454)
Net (decrease) increase in cash, cash equivalents and restricted cash		$	(78,424)	$	142,792
Net increase (decrease) in cash, cash equivalents and restricted cash						Net increase (decrease) in cash, cash equivalents and restricted cash	$	21,173	$	(78,424)

Cash provided by operating activities in the first nine months of ~~2021~~2022 and ~~2020~~2021 reflected ~~fluctuations in~~cash generated by net income along with changes in working capital.

Cash used for investing activities in the first nine months of ~~2021~~2022 included cash paid for the acquisition of Apria of $1.7 billion and ~~2020~~capital expenditures of $115 million for patient equipment and our strategic and operational efficiency initiatives associated with property and equipmentand capitalized software, partially offset by $29.7 million in proceeds related to the sale of property and equipment. Cash used for investing activities in the first nine months of 2021 included capital expenditures of $32.6 ~~million and $26.4~~ million for our strategic and operational efficiency initiatives associated with property and equipment, investments for increased manufacturing capacity in the Americas, and capitalized software. Cash provided by investing activities in the first nine months of 2020 included cash consideration received of $133 million from the sale of Movianto and proceeds of $6.0 million from the surrender of company-owned life insurance policies.

2527

Table of Contents

Cash used for financing activities in the first nine months of ~~2021~~2022 included ~~dividend payments~~proceeds from borrowings of ~~$0.5~~$1.7 billion related to the 6.625% senior notes due in 2030 (the 2030 Unsecured Notes), Term Loan A (as defined below), and Term Loan B (as defined below) for the first nine months of 2022, compared to $575 million related to the 4.500% senior unsecured notes due in 2029 (the 2029 Unsecured Notes) and ~~net repayments~~the accounts receivable securitization program for the first nine months of ~~$90.9 million~~2021. Borrowings under our revolving credit facility, net and accounts receivable securitization program of $30.0 million compared to ~~$0.5 million and $108~~net repayments of $90.9 million for the same period of ~~2020. We also had proceeds from borrowings~~2021. Repayments of ~~$575 million related to the 2029 Unsecured Notes and Accounts Receivable Securitization Program for~~debt in the first nine months of ~~2021,~~2022 included $3.0 million on our Term Loan B compared to ~~$150 million related to the Accounts Receivable Securitization Program for the first nine months of 2020.~~ ~~Financing activities also~~2021 included repayments of $553 million on our previous Term Loan A-2, previous Term Loan B, 3.875% Senior Notes due 2021 and 2024 Notes, and accounts receivable securitization program. Gross issuances and repayments under our amended accounts receivable securitization program were $697.7 million and $770.7 million for the first nine months of ~~2021 on our term loans, 2021 and 2024 Notes, and~~ 2022.~~Accounts Receivable Securitization Program,~~ ~~compared~~ ~~to $270 million~~ ~~in the same period of~~ ~~2020~~ ~~on our term loans and 2021 and 2024 Notes. We used $83.3 million of cash to repurchase~~ ~~$87.9 million~~ ~~aggregate principal amount of the 2021 and 2024 Notes during the first~~ ~~nine~~ ~~months of 2020.~~ We also paid ~~$13.9~~$42.6 million in financing costs in the first nine months of ~~2021~~2022, as compared to ~~$10.4~~$13.9 million ~~in financing costs~~ for the same period of ~~2020. In addition, we~~2021. We paid $15.4 million to terminate the remaining $300 million in notional value of interest rate swaps during the first nine months of 2021. Payments for taxes related to the vesting of restricted stock awards were ~~$19.3~~$44.6 million and ~~$3.6~~$19.3 million for the first nine months of ~~2021~~2022 and ~~2020,~~2021, which are included in Other, net.

Capital ~~resources~~.resources. Our sources of liquidity include cash and cash equivalents, ~~a revolving credit facility under~~ our Revolving Credit Agreement, ~~with Bank of America, N.A, as an administrative agent~~ and ~~collateral agent, and a syndicate of financial institutions, as lenders (the Credit Agreement), and the~~our Receivables ~~Securitization Program.~~Financing Agreement. The Revolving Credit Agreement provides a revolving borrowing capacity of ~~$300~~$450 million. We have $1.1 billion in outstanding term loans under a term loan credit agreement (the Credit Agreement). The interest rate on our ~~revolving credit facility~~Revolving Credit Agreement is based on a spread over a benchmark rate (as described in the Revolving Credit Agreement). The Revolving Credit Agreement matures in March 2026. The interest rate on the Term Loan A facility (Term Loan A) is based on either the Term SOFR or the Base Rate plus an Applicable Rate which varies depending on the current Debt Ratings or Total Leverage Ratio, determined as to whichever shall result in more favorable pricing to the Borrowers (each as defined in the Credit Agreement). The interest rate on the Term Loan B facility (Term Loan B) is based on either the Term SOFR or the Base Rate plus an Applicable Rate. The Term Loan A will mature in March 2027 and the Term Loan B will mature in March 2029.

At September 30, ~~2021~~2022, we had no borrowings and letters of credit of $27.9 million outstanding under our Revolving Credit Agreement. At December 31, ~~2020,~~2021, we had no borrowings ~~of $12.3 million and $103 million,~~ and letters of credit of $9.4 million ~~and $13.9 million~~ outstanding under our ~~credit agreements.~~Revolving Credit Agreement. At September 30, ~~2021~~2022 and December 31, ~~2020,~~2021, we had ~~$278~~$422 million and ~~$283~~$291 million, available for ~~borrowing.~~borrowing under our Revolving Credit Agreement. We also had letters of credit and bank guarantees, ~~outstanding~~which were issued outside of the Revolving Credit Agreement for ~~$2.2~~$2.3 million and ~~$1.6~~$2.2 million as of September 30, ~~2021~~2022 and December 31, ~~2020,~~2021, which supports certain leased facilities as well as other normal business activities in the United States and Europe. ~~These letters of credit and guarantees were issued outside of the revolving credit facility.~~

On March ~~10, 2021,~~29, 2022, we entered into an amendment to our accounts receivable securitization program (the Receivables ~~Securitization Program)~~Financing Agreement). Pursuant to the amended Receivables ~~Securitization Program,~~Financing Agreement, the aggregate principal amount of the loans made by the Lenders (as defined) will not exceed~~$450~~ $450 million outstanding at any time. The interest rate under the Receivables ~~Securitization Program~~Financing Agreement is based on a spread over a benchmark SOFR rate (as described in the ~~Third~~Fourth Amendment to the Receivables Financing Agreement). Under the Receivables ~~Securitization Program,~~Financing Agreement, certain of our subsidiaries sell substantially all of their accounts receivable balances to our wholly owned special purpose entity, O&M Funding LLC. The Receivables ~~Securitization Program~~Financing Agreement matures in March ~~2024.~~2025.

In May 2020, we entered into an equity distribution agreement, pursuant to which we may offer and sell, from time to time, shares of our common stock having an aggregate offering price of up to $50.0 million. We intend to use the net proceeds from the sale of our securities offered by this program for the repayment of indebtedness and/or for general corporate and working capital purposes. As of September 30, ~~2021~~2022 no shares were issued and $50.0 million of common stock remained available under the at-the-market equity financing program.

Table of Contents

We regularly evaluate market conditions, our liquidity profile and various financing alternatives to enhance our capital structure. From time to time, we may enter into transactions to repay, repurchase or redeem our outstanding indebtedness (including by means of open market purchases, privately negotiated repurchases, tender or exchange offers and/or repayments or redemptions pursuant to the debt’s terms). Our ability to consummate any such transaction will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. We cannot provide any assurance as to if or when we will consummate any such transactions or the terms of any such transaction.

The third quarter dividend of $0.0025 per share was paid in September 2021. The payment of future dividends remains within the discretion of the Board of Directors and will depend upon our results of operations, financial condition, capital requirements, current and future limitations under our Credit Agreement and other factors.

~~Table of Contents~~

We believe available financing sources, including cash generated by operating activities and borrowings under the Revolving Credit Agreement and Receivables ~~Securitization Program,~~Financing Agreement, will be sufficient to fund our working capital needs, capital expenditures, long-term strategic growth, payments under long-term debt and lease arrangements, ~~payments of quarterly cash dividends,~~ debt repurchases and other cash requirements. While we believe that we will have the ability to meet our financing needs in the foreseeable future, changes in economic conditions may impact (i) the ability of financial institutions to meet their contractual commitments to us, (ii) the ability of our customers and suppliers to meet their obligations to us or (iii) our cost of borrowing.

We earn a portion of our operating income in foreign jurisdictions outside the United States. Our cash and cash equivalents held by our foreign subsidiaries subject to repatriation totaled ~~$28.7~~$25.2 million and ~~$72.0~~$26.9 million at September 30, ~~2021~~2022 and December 31, ~~2020.~~2021. We continue to remain permanently reinvested in our foreign subsidiaries, with the exception of a subsidiary in Thailand. We have no specific plans to indefinitely reinvest the unremitted earnings of our foreign subsidiary located in Thailand as of September 30, ~~2021.~~2022. As such, we have recorded withholding tax liabilities that would be incurred upon future distribution to the U.S. There are no unrecognized deferred taxes as there is no outside basis difference unrelated to unremitted earnings for Thailand. We will continue to evaluate our foreign earnings repatriation policy in ~~2021~~2022 for all our foreign subsidiaries.

Impact of Inflation

The cost to manufacture and distribute our products is influenced by the cost of raw materials, finished goods, labor, and transportation. We have recently experienced inflationary pressure and higher costs as a result of the increasing cost of raw materials, finished goods, labor, transportation, and other administrative costs associated with the normal course of business. The increase in cost of raw materials and finished goods are due in part to a shortage in the availability of certain products, the higher cost of shipping, and inflation. We can only pass elevated costs onto customers in an effort to offset inflationary pressures on a limited basis. Future volatility of general price inflation and the impact of inflation on costs and availability of materials, costs for shipping and warehousing and other operational overhead could adversely affect our financial results.

Guarantor and Collateral Group Summarized Financial Information

We are providing the following information in compliance with Rule 13-01, “Financial Disclosures about Guarantors and Issuers of Guaranteed Securities” and Rule 13-02 of Regulation S-X, of with respect to our 2024 Notes. See Note 6 of the accompanying consolidated financial statements for additional information regarding the terms of the 2024 Notes.

The following tables present summarized financial information for Owens & Minor, Inc. and the guarantors of Owens & Minor, Inc.’s 2024 Notes (together, "the Guarantor Group"), on a combined basis with intercompany balances and transactions between entities in the Guarantor Group eliminated. The guarantor subsidiaries are 100% owned by Owens & Minor, Inc. Separate financial statements of the guarantor subsidiaries are not presented because the guarantees by our guarantor subsidiaries are full and unconditional, as well as joint and several.

Summarized financial information of the Guarantor Group is as follows:


Summarized Consolidated Statement of Operations - Guarantor Group	Nine Months Ended September 30, ~~2021~~2022
(Dollars in thousands)
Net revenue(1)	$	~~7,197,318~~7,236,833
Gross margin	~~1,086,054~~1,343,310
Operating income	~~265,888~~
~~Income from continuing operations, net of tax~~	~~158,735~~164,680
Net income	~~158,735~~67,007

(1)Includes ~~$297~~$200 million in sales to non-guarantor subsidiaries for the nine months ended September 30, ~~2021.~~2022.

Summarized Consolidated Balance Sheets - Guarantor Group September 30, 2021 December 31, 2020
(Dollars in thousands)
Total current assets $ 1,428,986 $ 1,559,248
Total assets 2,950,802 2,943,125
Current liabilities 1,456,508 1,374,800
Total liabilities 2,500,939 2,465,894

Table of Contents


Summarized Consolidated Balance Sheets - Guarantor Group	September 30, 2022		December 31, 2021
(Dollars in thousands)
Total current assets	$	1,629,336	$	1,449,917
Total assets	4,876,092		2,807,581
Current liabilities	1,677,527		1,399,499
Total liabilities	4,448,037		2,422,542

The following tables present summarized financial information for Owens & Minor, Inc. and the subsidiaries of Owens & Minor, Inc.’s 2024 Notes pledged that constitute a substantial portion of collateral (together, "the Collateral Group"), on a combined basis with intercompany balances and transactions between entities in the Collateral Group eliminated. The pledged subsidiaries are 100% owned by Owens & Minor, Inc. No trading market for the subsidiaries included in the Collateral Group exists.

Summarized financial information of the Collateral Group is as follows:

~~Table of Contents~~


Summarized Consolidated Balance Sheets - Collateral Group	Summarized Consolidated Balance Sheets - Collateral Group	September 30, 2021		December 31, 2020		Summarized Consolidated Balance Sheets - Collateral Group	September 30, 2022		December 31, 2021
(Dollars in thousands)	(Dollars in thousands)					(Dollars in thousands)
Total current assets	Total current assets	$	1,517,670	$	1,651,460	Total current assets	$	1,692,162	$	1,514,724
Total assets	Total assets	2,703,556		2,851,226		Total assets	4,788,819		2,729,455
Current liabilities	Current liabilities	1,422,746		1,356,024		Current liabilities	1,599,546		1,341,691
Total liabilities	Total liabilities	2,498,158		2,480,953		Total liabilities	4,415,095		2,398,694

The results of operations of the Collateral Group are not materially different from the corresponding amounts presented in our consolidated statements of operations.

Recent Accounting Pronouncements

For a discussion of recent accounting pronouncements, see our Annual Report on Form 10-K for the year ended December 31, ~~2020~~2021 and Note 1415 in the Notes to Consolidated Financial Statements, included in this Quarterly Report on Form 10-Q for the period ended on September 30, ~~2021.~~2022.

Forward-looking Statements

Certain statements in this discussion constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Although we believe our expectations with respect to the forward-looking statements are based upon reasonable assumptions within the bounds of our knowledge of our business and operations, all forward-looking statements involve risks and uncertainties and, as a result, actual results could differ materially from those projected, anticipated or implied by these statements. Such forward-looking statements involve known and unknown risks, including, but not limited to:

•our ability to achieve revenue and operating income goals may be affected by: COVID-19 related factors, risks and challenges, including among others, the length of time that the pandemic continues, and any worsening of the pandemic, including through any new variant strains of the underlying virus, or future pandemics, related governmental responses, the effectiveness, availability, and public acceptance of vaccines, a decrease in revenue ultimately resulting in less cash flow, longer duration in receivables collection, the need to expedite payments to important suppliers may grow, shifts in demand away from certain products we manufacture and distribute, reduced workforces which may be caused by, but not limited to, the temporary inability of the workforce to work due to illness, quarantine, or government vaccine and other mandates, temporary production and distribution center and office closures due to reduced workforces or government vaccine and other mandates, availability of raw materials, potential ~~resulting~~ labor negotiations or disputes, changes in the types and numbers of businesses that compete with us, including non-traditional competitors, and the aggressiveness of that competition, impacts of the pandemic or future pandemics on other third parties with whom we conduct business, the healthcare industry, and the broader business environment, and trends in elective surgeries and other healthcare spending not directly associated with COVID-19;

•competitive pressures in the marketplace, including intense pricing pressure;

•our ability to retain existing and attract new customers in a market characterized by consolidation among significant ~~customer consolidation~~customers, health insurers and/or other industry participants, and intense cost-containment initiatives;

Table of Contents

•our dependence on sales to certain customers or the loss or material reduction in purchases by key customers;

•our dependence on distribution of product of certain suppliers;

•our ability to successfully identify, manage or integrate acquisitions;

•our ability to successfully manage our international operations, including risks associated with changes in international trade regulations, foreign currency volatility, changes in regulatory conditions, deteriorating economic conditions, adverse tax consequences, and other risks of operating in international markets;

•the risk that problems may arise in successfully integrating the businesses of Apria and the Company, which may result in the combined company not operating as effectively and efficiently as expected and the risk that the combined company may be unable to achieve the anticipated synergies or cost savings, or it may take longer than expected to achieve those synergies;

•the effect of our acquisition of Apria and any developments relating thereto on our relationships with customers, suppliers and other third parties, as well as our operating results and business;

•uncertainties related to and our ability to adapt to changes in government regulations, including healthcare laws and regulations;

•risks arising from possible violations of legal, regulatory or licensing requirements of the markets in which we operate;

•uncertainties related to general economic, regulatory and business conditions;

~~Table of Contents~~

•our ability to successfully implement our strategic initiatives;

•the availability of and modifications to existing supplier funding programs and our ability to meet the terms to qualify for certain of these programs;

•the effect of price volatility in the commodities markets, including fuel price fluctuations, on our operating costs and supplier product prices;

•our ability to adapt to changes in product pricing and other terms of purchase by suppliers of product;

•the ability of customers and suppliers to meet financial commitments due to us;

•changes in manufacturer preferences between direct sales and wholesale distribution;

•changing trends in customer profiles and ordering patterns and our ability to meet customer demand for additional value-added services;

•our ability to manage operating expenses and improve operational efficiencies in response to changing customer profiles;

•our ability to meet performance targets specified by customer contracts under contractual commitments;

•availability of and our ability to access special inventory buying opportunities;

•the ability of business partners and financial institutions to perform their contractual responsibilities;

•our ability to continue to obtain financing, obtain financing at reasonable rates and to manage financing costs and interest rate risk, and our ability to refinance, extend or repay our substantial indebtedness;

•our financial flexibility may be limited by the restrictive covenants in our credit facilities and existing notes;

•the risk that information systems are interrupted or damaged or fail for any extended period of time, that new information systems are not successfully implemented or integrated, or that there is a data security breach in our information systems;

•we depend on reimbursements by payors, which could lead to delays and uncertainties in the reimbursement process;

•the home healthcare industry is highly competitive and fragmented, with limited barriers to entry which may make it susceptible to vertical integration by manufacturers, payors, providers (such as hospital systems) or disruptive new entrants;

•the risk that a decline in business volume or profitability could result in an impairment of goodwill or other long-lived ~~assets;~~assets, which would require us to record a significant charge to earnings in accordance with generally accepted accounting principles;

Table of Contents

•our ability to timely or adequately respond to technological advances in the medical supply ~~industry;~~and home healthcare industries and/or product and therapy innovations may make the services we currently provide obsolete or less competitive;

•our failure to adequately insure against losses, including from substantial claims and litigation, could have an adverse impact on our operations, financial condition, or prospects;

•recalls of any of our products, either voluntarily or at the direction of the Food and Drug Administration or another governmental authority, or safety risks or the discovery of serious safety issues with our products;

•our capitation arrangements may prove unprofitable if actual utilization rates exceed our assumptions;

•reductions in Medicare, Medicaid and commercial payor reimbursement rates could have a material adverse effect on our results of operations and financial condition;

•the costs associated with and outcome of outstanding and any future litigation, including product and professional liability claims;

•the market price for our common stock may be highly volatile;

•adverse changes in U.S. and foreign tax laws and the outcome of outstanding tax contingencies and legislative and tax proposals;

•our ability to successfully implement the expense reduction and productivity and efficiency initiatives;

•our ability to continue to comply with the terms and conditions of ~~Byram Healthcare’s~~Apria’s Corporate Integrity Agreement; and

•other factors detailed from time to time in the reports we file with the SEC, including those described in “Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, ~~2020,~~2021 our Form 10-Q for the three months ended March 31, ~~2021,~~2022, and our Form 10-Q for the three and six months ended June 30, ~~2021.~~2022

We undertake no obligation to update or revise any forward-looking statements, except as required by applicable law.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are subject to price risk for our raw materials, the most significant of which relates to the cost of polypropylene and nitrile used in the manufacturing processes of our ~~Global~~ Products & Healthcare Services segment. Prices of the commodities underlying these raw materials are volatile and have fluctuated significantly in recent years and in the future may contribute to fluctuations in our results of operations. The ability to hedge these commodity prices is limited.

We are exposed to risks of changes in shipping and freight costs, including container and other third party fees associated with the transportation of our products. Shipping and freight costs have fluctuated significantly in recent years and in the future may contribute to changes in our results of operations.

In the normal course of business, we are exposed to foreign currency translation and transaction risks. Our business transactions outside of the United States are denominated in the euro, Malaysian ringgit, Mexican peso, Thai baht and other currencies. We may use foreign currency forwards, swaps and options, where possible, to manage our risk related to certain foreign currency fluctuations.

We are exposed to market risk from changes in interest rates related to our borrowing under our Revolving Credit Agreement and Receivables ~~Securitization Program. We had~~Financing Agreement. Excluding deferred financing costs and third party fees, ~~$12.3~~we had $500 million in borrowings under our ~~revolving credit facility, $197~~Term Loan A, $597 million in

~~Table of Contents~~

borrowings under our ~~Receivables Securitization Program and $9.4~~Term Loan B, no borrowings under our Revolving Credit Agreement, $157 million in ~~letters of credit~~borrowings under ~~the Credit~~our Receivables Financing Agreement at September 30, ~~2021. We~~2022. After considering the effects of an interest rate swap agreement entered into during April 2022, we estimate an increase in interest rates of 100 basis points would result in a potential reduction in future pre-tax earnings of approximately ~~$2.2~~$8.5 million per year based on our borrowings outstanding at September 30, ~~2021.~~2022.

Due to the nature and pricing of our ~~Global Solutions~~Products & Healthcare Services segment distribution services, we are exposed to potential volatility in fuel prices. Our strategies for helping to mitigate our exposure to changing domestic fuel prices have included using trucks with improved fuel efficiency. We benchmark our domestic diesel fuel purchase prices against the U.S. Weekly Retail On-Highway Diesel Prices (benchmark) as quoted by the U.S. Energy Information Administration. The benchmark averaged ~~$3.16~~$5.00 and ~~$2.58~~$3.16 per gallon in the first nine months of ~~2021~~2022 and ~~2020.~~2021. Based on our fuel consumption in the first nine months of ~~2021,~~2022, we estimate that every 10 cents per gallon increase in the benchmark would directly reduce our ~~Global Solutions segment~~ operating income by approximately ~~$0.2~~$0.4 million on an annualized basis.We are also indirectly exposed to increased shipping and freight costs, including container and other third party fees associated with the transportation of our products due to

Table of Contents

changes in fuel prices. Changes in fuel prices have contributed to significant shipping and freight costs in recent years and in the future may contribute to changes in our results of operations.

Item 4. Controls and Procedures

We carried out an evaluation, with the participation of management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (pursuant to Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based upon that evaluation, the principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of September 30, ~~2021.~~2022. There was no change in our internal control over financial reporting that occurred during the period of this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. In connection with the Apria Acquisition, we are currently evaluating the acquired processes, information technology systems and other components of internal controls over financial reporting as part of our integration activities which may result in periodic changes. Such changes will be disclosed as required by applicable SEC guidance.

SEC guidance permits the exclusion of an evaluation of the effectiveness of a registrant's disclosure controls and procedures as they relate to the internal control over financial reporting for an acquired business during the first year following such acquisition. In the first quarter of 2022, we acquired Apria, Inc. This acquisition represented $2.0 billion of total assets and $620 million of revenues as of and for the nine months ended September 30, 2022. Management's evaluation and conclusion as to the effectiveness of the design and operation of the Company's disclosure controls and procedures as of and for the period covered by this report excludes any evaluation of the internal control over financial reporting of Apria, Inc.

Part II. Other Information

Item 1. Legal Proceedings

Certain legal proceedings pending against us are described in our Annual Report on Form 10-K for the year ended December 31, ~~2020.~~2021. Through September 30, ~~2021,~~2022, there have been no material developments in any legal proceedings reported in such Annual Report.

Item 1A. Risk Factors

~~The following description of~~Certain risk factors ~~updates and supplements risk factors associated with~~that we believe could affect our business ~~previously disclosed~~and prospects are described in our Annual Report on Form 10-K for the year ended December 31, ~~2020,~~2021 and our Form 10-Q for the three months ended March 31, ~~2021, and our Form 10-Q for~~2022. Through September 30, 2022, there have been no material changes in the ~~three and six months ended June 30, 2021. These~~ risk factors are in addition to those mentioned in other parts of this report and are not all of the risks that we face. We could also be affected by risks that we currently are not aware of or that we currently do not consider material to our business.

We are subject to risks related to public health crises or future outbreaks of health crises or other adverse public health developments such as the global pandemic associated with the 2019 novel coronavirus (COVID-19).

As a global healthcare solutions company, we are impacted by public health crises such as the global pandemic associated with COVID-19. The outbreak has significantly increased uncertainty and unpredictability of global economic conditions and the demand for and supply of raw materials and finished goods required for our operations. In addition, public and private sector policies and initiatives to reduce the transmission of COVID-19, such as the imposition of travel restrictions, the adoption of remote working and vaccination mandates, have impacted or may in the future impact our operations. In these challenging and dynamic circumstances, we continue to work to protect our teammates and the public, maintain business continuity and sustain our operations, including ensuring the safety and protection of the people who work in our production and distribution centers across the world, many of whom support the manufacturing and delivery of products that are critical in response to the global pandemic. We may restrict the operations of our production and distribution centers if we deem it necessary or if recommended or mandated by governmental authorities which would have an adverse impact on us. There is a risk that revenues will decrease ultimately resulting in less cash flow, we may see longer duration in receivables collection, and the need to expedite payments to important suppliers may grow. COVID-19 has impacted and may further impact our supply chains relative to global demand for our facial protection, nitrile gloves, and protective apparel products. COVID-19 has also affected and may further affect the ability of suppliers and vendors to provide products and services to us or to do so at acceptable quality levels or prices. Some of these factors could increase the demand for our products, while others could decrease demand or make it more difficult for us to serve customers. For example, the significant reduction in elective surgical procedures, which began mid-March of 2020, resulted in a material negative impact on our revenue for 2020. Any worsening of the COVID-19 pandemic or future outbreaks could result in similar reductions in elective surgical procedures or otherwise

~~Table of Contents~~

~~reduce demand for our products, any of which could have a material negative impact on our revenues and profit for future periods.~~

Although we have experienced significant growth in sales volumes for certain of our products (such as PPE) during the COVID-19 pandemic, as well as improved productivity and manufacturing output, there can be no assurance that such growth rates, increased sales volumes or other improvements will be maintained during or following the COVID-19 pandemic. We may also see a declinedescribed in such growth rates and sales volumes when the impact of the pandemic subsides and the healthcare system returns to a more normalized state. In particular, demand for such products may also decline as government-sponsored COVID-19 response stimulus, relief and production initiatives, such as those under the Defense Production Act (DPA) and the Coronavirus Aid, Relief and Economic Security (CARES) Act, expire. An accelerated shift of demand away from certain of our products and services could also adversely impact our revenues and profit margins.

Furthermore, COVID-19 has impacted and may further impact the broader economies of affected countries, including negatively impacting economic growth, the proper functioning of financial and capital markets, foreign currency exchange rates, and interest rates. For example, the continued spread of COVID-19 has led to disruption and volatility in the global capital markets, which increases the cost of capital and adversely impacts access to capital. Due to the speed with which the situation is developing and the uncertainty of its duration, any future outbreaks, similar pandemics, the timing of recovery, travel restrictions, business closures or business disruptions, a recession, depression or other sustained adverse market event resulting from the spread of the COVID-19 and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, we are not able at this time to predict the extent to which the COVID-19 pandemic, or any future outbreaks or similar pandemics, may have a material effect on our financial or operational results. However, the following adverse risks exist:

•Actions by the United States government or other foreign government could affect our business. These actions include purchasing products that we make or sell, imposing new product standards or allowing the use of alternative products, instituting regulatory requirements to purchase only locally manufactured products, exercising control over manufacturing or distribution operations, including use of the DPA, taking trade actions including the imposition or removal of tariffs or import / export controls, subsidizing the supply of products, imposition of vaccine mandates or other actions;

•Quarantine decisions by public or private entities may influence our ability to operate or our ability to ship or receive products. For example, if shipping companies cease or reduce land or sea freight channels, raw material and finished good deliveries may be slowed or stopped;

•~~Our customers may change their payment patterns or lose their ability to pay invoices, which could have a material adverse impact on our cash flow;~~

•Our suppliers may increase pricing or impose new purchasing requirements, such as minimum purchase quantities or pay-in-advance payment terms, which could have a material adverse impact on our cash flow;

•~~Raw materials or finished goods that we require for our operations may not be available, or pricing for such items may increase beyond the willingness of our customers to pay;~~

•~~New competitors may enter our market, including both small and large scale manufacturers;~~

•COVID-19 illness among our workers in manufacturing or distribution operations could impact our operations or compel the closure of one or more facilities for an unknown period of time. Labor relations in our facilities related to COVID-19 could also negatively impact our operations;

•~~We may invest in additional manufacturing capacity for which demand slows in the future, which could have a material adverse impact on our cash flow; and~~

•Technology infrastructure failures could materially inhibit our operations that currently include a substantial portion of remote work. For example, voice or data line failures resulting from natural, manmade or cyber-attack could impair our ability to operate.

We have incurred additional costs to ensure we meet the needs of our customers, including increasing our workforce in order to produce or distribute certain essential products for our customers, providing personal protective equipment to our workforce, incremental shipping and transportation costs, incremental technology costs, and additional cleaning costs throughout our facilities. We expect to continue to incur additional costs, which may be significant as we continue to implement operational changes in response to this pandemic, any future outbreaks or similar pandemics. Further, our management is focused on mitigating COVID-19, which has required and will continue to require, a large investment of time and resources across our enterprise and will delay other value added services and strategic initiatives. Additionally, some of our teammates are currently working remotely. An extended period of remote work arrangements, and any worsening of the COVID-19 pandemic, or future outbreaks, could strain our business continuity plans, introduce operational risk, including but not limited to cybersecurity risks, and impair our ability to manage our business. If we do not respond appropriately to the pandemic, any future outbreaks or similar pandemics, or if customers do not perceive our response to be adequate for the United States or our international markets, we could suffer damage to our reputation and our brands, which could adversely affect our business.

~~Table of Contents~~

~~The impact of COVID-19 may also exacerbate other risks discussed in Item 1A. Risk Factors in our~~ Annual Report onand First Quarter 2022 Form ~~10-K, any of which could have a material effect on us. This situation is changing rapidly and additional impacts may arise that we are not aware of currently.~~10-Q.

Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities

Item 5. Other Information

On October 28, 2022, the Company’s Board of Directors (the “Board”) adopted and approved, effective immediately, the amended and restated bylaws (as amended and restated, the “Amended and Restated Bylaws”) of the Company. The Amended and Restated Bylaws, among other things:

•revise procedures and disclosure requirements for shareholders to provide notice of the nomination of directors (outside of “proxy access”) and the submission of proposals for consideration at meetings of the shareholders of the Company;

Table of Contents

•clarify the power of the Board to set rules and procedures for, postpone, reschedule or cancel any meeting of shareholders previously scheduled, and clarify the power of the chair of a shareholder meeting to adjourn any meeting of stockholders;

•clarify the powers of the Board and the chair of a shareholder meeting to establish rules for the conduct of any meeting of shareholders;

•clarify that for the applicability of the plurality voting standard to an election of directors, an election remains “contested” (and the plurality voting standard continues to apply) even if the Board determines that a shareholder’s nomination notice does not comply with the advance notice bylaws;

•provide that the size of the Board can be fixed from time to time by resolution of the Board;

•adopt a forum selection bylaw to provide that (i) shareholder suits and other derivative actions asserted against the Company or its directors and officers be brought only before the United States District Court for the Eastern District of Virginia and (ii) the U.S. federal district courts shall be the exclusive forum for the resolution of claims under the Securities Act of 1933, as amended; and

•make certain other administrative, modernizing, clarifying and conforming changes.

The foregoing description of the Amended and Restated Bylaws is not complete and is qualified in its entirety by reference to the complete text of the Amended and Restated Bylaws, which is filed as Exhibit 3.1 hereto and is incorporated herein by reference.

Item 6. Exhibits

(a)Exhibits


2.1						Agreement and Plan of Merger, dated as of January 7, 2022, by and among Owens & Minor, Inc., StoneOak Merger Sub Inc. and Apria, Inc. (incorporated by reference to Exhibit 2.1 to Current Report on Form 8-K filed with the SEC on January 10, 2022, File No. 001-09810).

3.1						Amended and Restated Bylaws of the Company effective ~~April 29, 2021 (incorporated herein by reference to the Company’s Current Report on Form 8-K, Exhibit 3.1, dated May 3, 2021)~~October 28, 2022

4.1						Indenture dated March ~~10, 2021,~~29, 2022 by and among ~~Owens & Minor, Inc.,~~the Company, the guarantors named therein and Regions Bank, as ~~Trustee~~trustee (incorporated herein by reference to the Company’s Current Report on Form 8-K, Exhibit 4.1, dated March ~~11, 2021)~~29, 2022)

4.2						Form of Global Note for the ~~4.500%~~6.625% Senior Notes due ~~2029 (included as Exhibit A to Exhibit 4.1 hereto)~~2030 (incorporated herein by reference to the Company’s Current Report on Form 8-K, Exhibit 4.2, dated March ~~11, 2021)~~29, 2022)

4.3						~~Sixth~~Seventh Supplemental Indenture dated as of March ~~10, 2021,~~29, 2022, by and among ~~Owens & Minor, Inc.,~~the Company, the guarantors ~~signatory thereto~~named therein and U.S. Bank National Association, as trustee (incorporated herein by reference to the Company’s Current Report on Form 8-K, Exhibit 4.3, dated March ~~11, 2021).~~29, 2022)

4.4						First Supplemental Indenture dated as of March 29, 2022, by and among the Company, the guarantors named therein and Regions Bank, as trustee, to the Indenture dated as of March 10, 2021 (incorporated herein by reference to the Company’s Current Report on Form 8-K, Exhibit 4.4, dated March 29, 2022)

4.5						First Supplemental Indenture dated as of March 29, 2022, by and among the Company, the guarantors named therein and Regions Bank, as trustee, to the Indenture dated of March 29, 2022 (incorporated herein by reference to the Company’s Current Report on Form 8-K, Exhibit 4.5, dated March 29, 2022)

10.1						~~Agreement of Resignation, Appointment, and Acceptance, dated as September 10, 2021, by and among~~Amendment No. 3 to the Owens & Minor, Inc.~~, U.S. Bank National Association, as Prior Trustee, and Regions Bank, as Successor Trustee~~ 2018 Stock Incentive Plan - (incorporated herein by reference to our Form 10-Q, Exhibit 10.7, dated May 3, 2022)**

10.2						~~Form~~Executive Separation Agreement and General Release, dated as of October 12, 2022, by and between Jeffrey T. Jochims and Owens & Minor, Inc. ~~Restricted Stock Agreement under the Company's 2018 Stock Incentive Plan~~

~~10.3~~						~~Form of Owens & Minor, Inc. Restricted Stock Unit Award Agreement under the Company's 2018 Stock Incentive Plan~~**

22.1						List of Guarantor Subsidiaries ~~(incorporated herein by reference to our Annual Report on Form 10-K, Exhibit 22.1, for the year ended December 31, 2020)~~

Table of Contents



22.2						List of Subsidiaries Pledged as Collateral

31.1						Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2						Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1						Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

~~Table of Contents~~

32.2

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File (formatted as inline ~~XBRL~~iXBRL and contained in Exhibit 101)

* Certain exhibits and schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. We hereby undertake to furnish copies of such omitted materials supplementally upon request by the SEC.

** Management contract or compensatory plan or arrangement

3335

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		Owens & Minor, Inc.
		(Registrant)

Date:	November ~~3, 2021~~2, 2022	/s/ Edward A. Pesicka
		Edward A. Pesicka
		President, Chief Executive Officer & Director

Date:	November ~~3, 2021~~2, 2022	/s/ ~~Andrew G. Long~~Alexander J. Bruni
		~~Andrew G. Long~~Alexander J. Bruni
		Executive Vice President & Chief Financial Officer

3436


	Global Solutions		Global Products		Consolidated
Carrying amount of goodwill, December 31, 2020	$	283,905	$	110,181	$	394,086
Currency translation adjustments	—		(7,393)		(7,393)
Carrying amount of goodwill, September 30, 2021	$	283,905	$	102,788	$	386,693